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Abbreviations 
AIDS Acquired Immunodeficiency Syndrome 
Amp      Ampicillin 
APS       Ammonium Persulphate 
Ax  Absorbance at λ=X 
BFP Blue Fluorescent Protein 
BSA       Bovine serum albumine 
CA HIV Capsid Protein 
CAT Chloramphenicol Acetyl Transferase 
CDK9 Cyclin Dependent Kinase 9 
CFP Cyan Fluorescent Protein 
Chl Chloramphenicol 
CIAP        Calf Intestinal Alkaline Phosphatase 
CTD 
C-Terminal Domain of the major subunit of 
RNA Polymerase II 
Da Dalton 
dH2O Sterilized Water 
ECL Enhanced Chemoluminiscense 
EDTA  Ethylenediamminetetraacetate 
EGFP Enhanced Green Fluorescent Protein 
ESS2  Exon splicing silencer 2 
E. coli      Eschericia coli 
FPLC Fast Pressure Liquid Chromatography 
GFP Green Fluorescent Protein 
gp Glycoprotein 
HAART Highly Active Anti-Retroviral Therapy 
HAT  Histone Acetyl Transferase 
His-tag Polyhistidine sequence 
HIV Human Immunodeficiency Virus 
HIV-1 Human Immunodeficiency Virus type 1 
HIV-2 Human Immunodeficiency Virus type 2 
HSPG Heparan Sulfate Proteoglycan 
HXB2 A particular strain of HIV-1 
HXB3 A particular strain of HIV-1 
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IMAC Immobilized metal ion affinity 
chromatography 
IN HIV-1 Integrase 
IPTG        Isopropyl β-D-thiogalactoside 
kDa  Kilodalton 
LAI A particular strain of HIV-1 
LB Luria Bertani/Luria Broth 
LTR Long Terminal Repeat 
MA       Matrix protein 
mAb    Monoclonal Antibody 
MCAC Metal Chelate Affinity Chromatography 
MCS  Multiple Cloning Site 
MVP5180 A particular strain of HIV-1 
NC HIV Nucleocapsid Protein 
NES Nuclear Export Signal 
NLS Nuclear Localization Signal 
NMR Nuclear Magnetic Resonance 
NOS Nucleolar Localisation Signal 
NTEF Negative Transcription Elongation Factors 
O/n Over Night 
PAGE Polyacrylamide Gel Electrophoresis 
PBS          Phosphate-buffered saline 
PCR Polymerase Chain Reaction 
PFA  Paraformaldehyde 
PIC HIV-1 Preintegration Complex 
PKR  A dsDNA Dependent Protein Kinase 
PMSF  Phenyl Methyl Sulfonyl Fluoride 
POD Horseradish Peroxidase 
PR HIV-1 Protease 
PTEF Positive Transcription Elongation Factor 
RFP Red Fluorescent Protein 
RGD The amino acid triplet arginine-glycine-
aspartic acid sequence 
RNAP II RNA Polymerase II 
RT HIV-1 Reverse Transcriptase 
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SDS  Sodium Dodecyl Sulphate 
SDS-PAGE Sodium Dodecyl Sulphate Polyacrylamide 
Gel Electrophoresis 
SIV  Simian Immunodeficiency Virus 
SU  Surface Protein 
TAR  Trans-Activating Response Element 
Tat  Trans-cellular Transactivator Protein 
Tat72 One-exon encoded Tat protein 
Tat86  Two-exon encoded Tat protein comprising 86 
amino acids 
Tat101  Two-exon encoded Tat protein comprising 
101 amino acids 
Tat115 Two-exon encoded Tat protein comprising 
115 amino acids 
TEMED Tetramethylendiamid 
Tm  Melting temperature of dsDNA 
TM  Transmembrane Protein 
u Units of enzyme activity 
YFP Yellow Fluorescent Protein 
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Aims and summary of the present study 
The HIV-1 encoded Tat protein is essential for viral propagation. It transactivates the viral 
LTR promoter, and it also has transcellular activities as it can be transferred from one cell to 
another. Most studies of the Tat protein have been performed using Tat from a few 
laboratory-adapted strains of HIV-1. These strains encode an 86 amino acid variant of the 
protein. However, most strains encode a 101 amino acid long variant. It has been speculated 
that the 86 amino acid version is a truncated form of the protein, and that it does not have all 
the properties of the full-length variant. 
The main aims of this study were (I) to construct two full-length wild type variants of the tat 
gene. This would allow the study of the properties of these full-length versions of Tat. (II) To 
perform a computational analysis of the proteins, to predict their properties. (III) To insert the 
genes into bacterial expression vectors, which would allow the purification of the Tat protein, 
and (IV) the Tat proteins would then tested for transcellular activation. (V) The genes were 
also to be inserted into vectors allowing production of fusion proteins with the fluorescing 
protein EGFP. (VI) The intracellular distribution of these proteins was then to be studied in 
transfected cells by fluorescence microscopy, and (VII) the transactivating properties of the 
EGFP-Tat fusion proteins was then to be verified using an LTR-reporter gene construct. 
(I) The HXB3 clone encodes an 86 amino acid Tat protein and was available in our 
laboratory. It was decided to construct a 101 amino acid Tat protein based on the sequence of 
this clone. Then the abilities of the protein would be comparable to those of the Tat86 protein 
available for study. A point mutation was made to alter the stop codon at codon 87. This gene 
was then named tat101. A second tat gene was constructed in order to study differences 
among Tat proteins from different strains. This second tat gene was made based on the 
sequence of the MVP5180 strain of HIV, and was called tat115. 
(II) The computer analyses showed a possible novel domain, named the EK domain, as well 
as a potential new nuclear localization signal in the Tat101 protein. 
(III) The tat genes were successfully inserted into the pRSET-C vector. The Tat101 protein 
was purified by the aid of an N-terminal 6xhis tag. There were problems purifying the Tat115 
protein, so this was not done. 
(IV) The Tat101 protein was added to the media of cultured COS-7 cells transfected with and 
LTR-CAT plasmid. And it was shown that this induced the expression of the reporter protein. 
(V) The tat genes were successfully inserted into the pEGFP-C1 vector.  
(VI) By fluorescence microscopy the Tat101 and Tat115 proteins fused to EGFP were shown 
to be located in the nucleus and the nucleolus when expressed in COS-7 cells. 
(VII) It was shown that the EGFP-Tat115 and EGFP-Tat101 fusion proteins induced the 
expression of the CAT reporter protein when the LTR-CAT plasmid was co-transfected with 
either of the EGFP-Tat plasmids. 
 
Figure 0.1: An overview of the aims of this study. 
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1 Introduction 
1.1 HIV and AIDS 
The Human Immunodeficiency Virus (HIV) is a retrovirus of the lentivirus family. Lenti 
means slow, and the name reflects the long incubation period, the time it takes from infection 
until the associated disease starts developing. The virus is mainly transmittable through bodily 
fluids, primarily blood and semen. A person infected with the virus has a gradual inactivation 
of the immune system. Characteristically, the CD4+ T cells are depleted. This causes the 
disease Acquired Immunodeficiency Syndrome (AIDS). With their immune system in 
disarray the bearer of the virus is more susceptible to opportunistic infections and several, 
otherwise rare, types of cancer (Blattner, 1999; Tirelli et al., 2002; http://www.who.int). 
AIDS is a global epidemic. At the end of 2002 the number of people with HIV or AIDS in 
Norway was estimated to 2555. Globally it was estimated to 42 million. Of these 29.4 million 
were located in the southern parts of Africa where the disease is most widespread. More than 
25 million people have died AIDS-related deaths since the discovery of this disease in 1981 
(http://www.unaids.org; www.fhi.no). The infrastructure of those countries where the disease 
is most prevalent is threatened by a future collapse (reviewed by Piot et al., 2001). 
Several steps are being taken to combat this disease. One important step is health education 
campaigns that inform the public of how AIDS is transmitted, thereby trying to limit the 
number of people being exposed to the virus. Another step is the development of drugs to 
treat the disease. Research that gives us knowledge of the molecular mechanisms of how the 
virus interacts with its host will drive forward the development of novel therapies. No known 
therapy can completely rid the body of the virus. Several vaccines are currently in different 
stages of clinical trials in humans. These vaccines are, however, therapeutic vaccines, aimed 
at controlling the infection rather than preventing it (reviewed by Amara and Robinson, 
2002). A combination of drugs called HAART (Highly Active Anti-Retroviral Therapy) has 
proved very efficient in stalling the disease, but there are serious problems with toxic side 
effects (Louie et al., 2002; http://hivmedicine.com/index.htm). 
A major problem in the development of treatments and therapies for HIV infection is the high 
frequency with which the virus mutates. Mutations also cause the changes that make the 
immune system unable to recognize the virus (Wei et al., 2003). The viral encoded reverse 
transcriptase protein (RT) transcribes genomic RNA to double stranded DNA, which is 
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integrated into the host genome. RT does not have a proof-reading activity, and is the main 
cause of mutations of the virus (Preston and Dougherty, 1996). This accounts for the many 
different strains and subtypes of HIV. 
HIV is classified as two major types: HIV-1 
and HIV-2. HIV-1 is the most common and 
infectious of these two, and can further be 
divided into 3 groups: M, N and O. HIV-1 
Group M is by far the most important 
contributor to the AIDS pandemic and can 
further be divided into 10 subtypes, A-H and J-
K (http://hiv-web.lanl.gov). When comparing 
the sequences of different strains of HIV with 
those of Simian Immunodeficiency Virus 
(SIV), the interspersion in the evolutionary 
tree (see figure 1.1) suggests shared viral 
lineages (Hahn et al., 2000; Korber et al., 
2000), and that HIV has arisen when SIV has 
been transmitted from its natural simian host to 
humans. It also suggests that this sort of 
transmission has occurred several times. For 
instance, it is likely that HIV-1 groups M, N 
and O have arisen from separate zoonotic Figure 1.1: Phylogenetic (i.e. evolutionary) tree of
different strains of HIV-1 and SIV CPZ, showing how
they are related. The length from one indicated point to
another shows relative genetic distance. HIV-1 group M
is the main cause of the global pandemic and all the
subtypes within are likely to have descended after a single
zoonotic transfer (cross-species transfer from the natural
host, a non-human, to a human) of a simian virus. HIV
groups N and O are likely to have arisen after separate
zoonotic transmissions. SIV CPZ P.t.t.: strains of SIV
found in Pan troglodytes troglodytes, a subspecies of
chimpanzee. SIV CPZ P.t.s.: a strain of SIV found in a
chimpanzee of the subspecies Pan troglodytes
schweinfurthii. (Modified from Reeves and Doms, 2002) transmissions of SIV. HIV-1 and HIV-2 are 
related to quite different strains of SIV, SIV from chimpanzees, SIVCPZ, and sooty mangabey, 
SIVSM respectively. Despite its name, most strains of SIV do not cause disease in their natural 
host. 
A sample from 1959 shows that HIV-1 was in a human population already at that time (Zhu et 
al. 1998) and sequence analyses estimate that the last common ancestor of the HIV-1 M group 
existed in a human host some time between 1915 and 1941 (Korber et al. 2000).  
What effect the divergence in sequence between the different strains has on virulence, 
transmission rates and general epidemiology has not been clarified, but the different HIV-1 
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types all have the same basic structure (shown in figure 1.2), and the same life cycle (figure 
1.3). 
1.2 The physical and genetic structure of HIV 
A model of the virus particle is depicted in figure 1.2.A. It is spherical with a membrane that 
originates from the host cell plasma membrane. Located on the surface of the membrane is a 
protein called gp120 or the Surface protein (SU). It is anchored through gp41, the 
transmembrane 
 
 
Figure 1.2: Organisation of the HIV-1 virion
and genome: A) The HIV-1 virus particle,
showing the most important parts (see the text
for a more detailed description). B) The HIV-1
genome. The genes gag, pol and env encode
polyproteins that are proteolytically cleaved to
produce the mature virion proteins. The viral
protease (PR) cleaves Gag and Gag-Pol
polyproteins, while the Env polyprotein is
cleaved by a cellular protease. Gag encodes the
Matrix protein (MA), the major Capsid protein
(CA), the Nucleocapsid protein (NC) and p6;
from pol, Protease, Reverse Transcriptase (RT)
and Integrase (IN); and from env, the surface
subunit (SU) gp120 and the Transmembrane
subunit (TM) gp41 are encoded. The regulatory
proteins Tat and Rev, as well as the accessory
proteins Vif, Vpr, Vpu and Nef are all encoded
by their own open reading frames in the HIV-1
genome. The Long Terminal Repeat, LTR, is
used as a promoter. The HIV-1 mRNA contains
several splicing sites. Fully spliced it encodes
Tat, Rev and Nef proteins. The other proteins are
expressed when Rev downregulates the splicing
of this mRNA. The proteins encoded by gag and
pol also have alternate names, based on their
molecular weight. MA=p17, CA=p24, NC=p7,
RT=p66/p51 (a dimer where the two subunits are
differently cleaved), IN=p32, PR=p11.  
A 
B 
Transmembrane protein (TM). TM is embedded in the membrane. Underneath the plasma 
membrane is an icosahedron made by the Matrix protein (MA). Inside the icosahedron the 
Capsid protein (CA) forms a cone in the mature virus particle. This cone is called the core 
particle. Within this cone are the proteins Reverse Transcriptase (RT), Integrase (IN), 
Protease (PR), and Nucleocapsid (NC). The latter is associated with the two RNA copies of 
the HIV genome. This association serves to stabilize the genome. In addition the viral particle 
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contains the viral proteins Nef, Vif, Vpr and p6, as well as several cellular factors (Frankel 
and Young 1998; Ott et al., 2000). Among these is the tRNA (tRNALys) that is used as primer 
for initiation of reverse transcription. 
Depicted in figure 1.2.B is the organisation of the HIV-1 genome, an approximately 9200 bp 
long single stranded RNA. It contains the gag, pol and env genes. This is typical for all 
retroviruses. These genes encode polyproteins, which are cleaved by proteolysis into 
individual proteins. The Gag polyprotein is cleaved into the proteins MA, CA and NC that 
make up the core of the virion, as well as p6 found within the virion. Env encodes the 
membrane proteins SU and TM. Pol encodes the enzymes PR, RT and IN. The HIV genome 
further contains the genes for Tat and Rev, proteins that regulate HIV gene expression, as well 
as genes for four accessory proteins, Nef, Vif, Vpr and Vpu. As seen in the figure, these 
additional proteins are encoded by separate and overlapping ORFs (reviewed by Frankel and 
Young, 1998). 
1.3 The life cycle of HIV 
The life cycle of HIV is outlined in figure 1.3. HIV-1 infects a cell as the plasma membrane 
of the virus particle fuses with the cellular plasma membrane. This is a result of the 
interaction between SU in the viral membrane and the cell-surface receptor CD4. The fusion 
of these membranes also requires a coreceptor. The coreceptors commonly used by HIV-1 are 
CXCR4, which is located on the surface of CD4 T Helper cells; or CCR5, which is located on 
the surface of macrophages and a subset of the CD4 T Helper cells. Which coreceptor a virus 
can use determines its tropism. The fusion of viral and cellular membranes leads to the release 
of the viral core particle into the cytoplasm. The particle develops into a looser structure. 
Within this structure the RNA genome is reverse transcribed. This renders a linear double 
stranded DNA molecule. The transformed core particle, a DNA protein complex called the 
preintegration complex (PIC), moves from the cytoplasm into the nucleus. There IN integrates 
the viral DNA into a host chromosome, thus making the viral genome a stable genetic element 
of the infected cell, a provirus. 
The first full-length viral mRNAs to be produced will for the most part be doubly spliced. 
These mRNAs encode the Tat, Rev and Nef proteins. Tat and Rev function in feedback loops 
and will travel to the nucleus. Tat will increase the production of functional HIV mRNAs 
through a mechanism discussed later. Rev transports unspliced and singly spliced viral 
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mRNAs to the cytoplasm where the mRNAs are translated. This leads to the expression of the 
other HIV proteins. 
 
Fig 1.3: The HIV life cycle. The details are outlined in the text. 
Full-length, unspliced mRNA transcribed from the provirus is packaged into the new virions 
and used as genomic RNA. It is also used as messenger RNA for synthesis of both Gag and 
Gag-Pol polyproteins. The latter is made when the ribosome shifts reading frames while 
translating this mRNA. This happens approximately every 20th round of translation. The Gag 
and Gag-Pol polyproteins will associate at the plasma membrane and initiate the assembly of 
the core particle. The plasma membrane where they assemble is enriched with the SU and TM 
proteins. These two proteins are formed as gp160 polyprotein and cleaved by a cellular 
protease in the Golgi. The core particle becomes encapsulated within plasma membrane as it 
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is budded off from the cell. Maturation takes place during or immediately after the budding of 
this particle. A functional core particle is formed in this process when the viral protease 
cleaves the Gag and Gag-Pol polyproteins (reviewed by Frankel and Young, 1998).  
1.3.1 Regulation of transcriptional activity 
The Tat protein has several functions. Most importantly, it regulates the extent to which HIV 
mRNA is elongated during transcription. As illustrated in figure 1.4, in the absence of Tat 
most transcripts are short RNAs less than 100 bases in length. These are degraded by cellular 
mechanisms. A few transcripts are full-length. This means that the production of HIV proteins 
is very low, and the production of full-length HIV mRNA is at a minimum. The first full-
length transcripts that are produced become 
fully spliced and encode the HIV early 
proteins. Among these is the Tat protein. The 
presence of Tat protein leads to the 
production of more full-length transcripts; a 
200-300-fold increase of these when Tat is 
present has been reported (Jeang et al., 
1999). This indicates that Tat functions in a 
positive feedback loop. It upregulates its 
own expression along with that of the other 
HIV proteins. Thus it accelerates the viral 
life cycle and the virus production. 
Studies of the mechanism behind this 
regulation have revealed previously unknown 
mechanisms of regulation of gene 
expression. 
Transcription as performed by RNA 
Polymerase II (RNAP II) can be divided into three parts: initiation of transcription, elongation 
of the RNA molecule, and termination. When the HIV genome is transcribed the RNA 
Polymerase II will usually stop synthesizing the mRNA after approximately the first 59 
nucleotides. At this point the initiation complex will be transformed into an elongation 
complex, which includes different factors. Among the factors that associate with the 
elongation complex are Negative Transcription Elongation Factors (NTEFs). These are 
Figure 1.4: The net effect of Tat in the regulation of HIV
mRNA. A: In the absence of Tat most RNA transcripts of
the HIV genome are less than 100 basepairs, and will
quickly be degraded. A few transcripts are full-length. B:
When The Tat protein is present the situation changes.
The amount of full-length transcripts can be increased
some hundredfold. 
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thought to be responsible for the halt in transcription by dephosphorylating the C-Terminal 
Domain (CTD) of the major subunit of RNA Polymerase II. Positive Transcription Elongation 
Factors (PTEFs), are required to overcome this halt in transcription and Tat functions by 
recruiting one such PTEF to the elongation complex (Price, 2000). 
 
If the RNA that has been transcribed up to this point is at least 44 nucleotides long it will form 
the stem-loop structure known as TAR, the transactivation response element. When present, 
Tat will bind to a small bulge in the TAR structure (figure 1.5.A). The protein Cyclin T1 will 
bind to Tat and the loop of TAR. Cyclin T1 is a part of the Positive Transcription Elongation 
Factor b complex, PTEFb. Another component of PTEFb is Cyclin Dependent Kinase 9 
(CDK9), which binds directly to Cyclin T1. The Tat-TAR-PTEFb complex will associate with 
the stalled RNAP II complex. Subsequently TAR will be released from the complex (Keen et 
al., 1997). CDK9 will then phosphorylate the CTD (figure 1.5.B) as well as other factors. 
These other factors include at least one subunit of an NTEF (Ping and Rana, 2001; reviewed 
by Kobor and Greenblatt, 2002). This phosphorylation seems to be required to overcome the 
halt in transcription, and this allows the RNAP II complex to proceed to make a complete 
transcript. 
Figure 1.5: A representation of how Tat helps to overcome the block of the transcription of the HIV genome. A) The RNA
polymerase II complex has transcribed the stem-bulge-loop TAR, which lies just downstream of the promoter. Tat has bound
to TAR and to Cyclin T1, thus starting the formation of a complex with the PTEFb. PTEFb includes a kinase, cdk9 (which
binds to Cyclin T1). B) When the Tat-PTEFb complex becomes part of the RNAP II elongating complex, TAR is released
and cdk9 will phosphorylate the C-terminal domain of the major subunit of RNAPII. This makes the transcription complex
able to continue transcribing the HIV-1 genome. 
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In addition to this it has been demonstrated that Tat interacts with several other cellular 
factors involved in transcription (Kobor and Greenblatt, 2002). Tat has also been shown to 
associate with Histone Acetyl Transferases, HATs (Benkirane et al., 1998; Kiernan et al., 
1999). When DNA is to be transcribed these participate in unravelling the nucleosome 
structures in which the DNA is packed. 
1.3.2 The transcellular activity of Tat 
The Tat protein accumulates in the nucleus and the nucleoli of the cell. It is a 
nucleocytoplasmic shuttle protein, moving back and forth between the nucleus and the 
cytoplasm (Stauber and Pavlakis, 1998). It is secreted from cells (Ensoli et al., 1993) and can 
be detected in sera from HIV positive patients (Westendorp et al., 1995). It can also enter 
cells from the outside (Helland et al. 1991; Mann and Frankel 1991; Ensoli et al. 1993; 
Verhoef et al. 1996; Valvatne et al., 1996; Staalesen, 1999). It is not known how Tat can be 
transported from the nucleus to the cytoplasm since a nuclear export signal (NES) has not 
been identified. Nor is it known by which mechanism Tat is secreted from cells. However, it 
is known that the basic domain of Tat mediates import into the cell as well as into the nucleus 
(Dang and Lee, 1989). This is the same domain as the one with which Tat binds to TAR. Tat 
enters cells by binding to Heparan Sulfate Proteoglycans (HSPG) on the cell surface (Tyagi et 
al., 2001). These are part of the extracellular matrix and nearly all types of cells have them, 
hence Tat can enter almost any kind of cell.  
 
Figure 1.6: Trafficking of the Tat protein. 1) Tat is a shuttle protein moving back and forth between the nucleus and the 
cytoplasm. 2) Tat may be secreted from cells and 3) be taken up by another cell, or alternately 4) interact with cell-surface 
receptors of either A) the cell from which it originated in an autocrine loop or B) a nearby cell. 5) Interaction with cell-
surface receptors may trigger signal transduction pathways that affect the gene expression of the cell. 
Figure 1.6 shows an overview of the trafficking of the Tat protein. Tat’s ability to traverse 
from one cell to another means that Tat may affect gene expression in neighbouring cells, 
cells that might not be infected with HIV. This can be a result of Tat interacting with 
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transcription factors inside this other cell, but it can also be the result of Tat’s interaction with 
either of several receptors on the cell surface (Rusnati et al., 2000). This would trigger signal 
chains that ultimately affect the gene expression of the cell. Through these Tat may be linked 
to several of the pathogenic (i.e. disease-causing) effects caused by HIV infection.  
1.3.3 Implicating Tat in the pathogenic effects of HIV 
Tat has been implicated in a multiplicity of functions related to the HIV life cycle and the 
diseases associated with HIV. The effects of Tat on the immune system can be divided into 
two parts: Tat as a transcriptional activator of the HIV genome has a direct effect on the speed 
with which the virus replicates, and thus also how fast the disease progresses; and secondly, 
Tat affects the expression of cellular genes, directly and indirectly. 
Tat can affect cellular gene expression in two ways: intracellularly by direct contact with 
components of the transcriptional machinery, or extracellularly through receptors on the 
surface of the cell. The latter will trigger signalling pathways that will lead to a change in cell 
function/cellular gene expression. Extracellular Tat functions as a chemoattractant on several 
different cell types of the immune system (Benelli et al. 2000). By moving into the vicinity of 
a cell productively infected with HIV these attracted cells are more easily infected. 
Extracellular Tat also induces immune cells to produce several cytokines, which regulate the 
immune response (Nath et al. 1999). This may lead to a dysregulation of the immune 
response. Tat induces the expression of monocyte chemoattractant protein-1 in astrocytes. If 
there has been a productive infection of HIV in the brain the monocytes that are indirectly 
attracted by Tat will also be induced to secrete eicosanoids and inflammatory cytokines that 
are toxic to the cells of the central nervous system. This induces dementia (Conant et al., 
1998). Tat is also an angiogenic factor and induces the production of angiogenic factors in 
macrophages. This means that the presence of Tat leads to a production of blood vessels. This 
is important in the development of tumours. For instance, Tat increases the growth rate of 
cells derived from the characteristic skin cancer Kaposi’s Sarcoma which affects an 
uncommonly high percentage of HIV patients, especially gay men (Blattner, 1999; Louie et 
al., 2002). 
The depletion of CD4+ T cells is the most characteristic trait of HIV infection. When HIV 
infects these cells it does lead to their eventual death, but the massive loss of these cells 
cannot be explained by this alone. Depending on which cell surface coreceptor the SU protein 
can interact with, HIV can infect CD4+ T cells, macrophages or both. Usually when a person 
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is infected with HIV it will be with a macrophage tropic virus. In less than half of the patients 
there will be a shift in tropism of the virus so that it can also infect the CD4+ T cells (Weiss, 
2000). The loss of these cells in the absence of their infection has been ascribed to apoptosis, 
programmed cell death (Gougeon and Montagnier, 1993). Extracellular Tat has been reported 
to induce several effects on uninfected CD4+ T cells: activation, functional unresponsiveness 
and apoptosis (Westendorp et al., 1995; Ott et al. 1997; Bartz and Emerman, 1999). This 
would make them more susceptible to infection by HIV, ineffective or dead, respectively.  
The phenomenon illustrated in figure 1.4 is also dependent on the levels of Cyclin T1 of 
PTEFb. An important part of the immune response is that promonocytic cell lines differentiate 
to macrophages and that T Cells are activated. When this happens the levels of Cyclin T1 
increase dramatically (Price, 2000). The expression of HIV in these cells is hampered until 
this has happened. But as the Cyclin T1 levels rise, the virus production of the cell will 
increase and normal functions of the cell will be downregulated so that the cell cannot take 
part in the intended immune response. 
The virulence of HIV varies among strains, as does the sequence of the Tat protein. When 
HIV-1 Tat has been studied mostly variants derived from viruses of group M, subtype B have 
been used.  
1.3.4 An overview of the Tat protein  
In most wild type isolates of HIV-1, the Tat protein comprises 101 amino acid residues. The 
first 72 of these are encoded by tat exon-1, and residues 73-101 are encoded tat exon-2 (figure 
1.2.B). In the first stages of HIV infection the cell will produce Tat protein encoded by both 
exons, but in the later stages as Rev transports unspliced and singly spliced mRNA to the 
cytoplasm, the cell will produce one exon Tat protein (Purcell and Martin, 1993). The loss of 
the second exon in late stages of HIV infection might be to slow down or shut off the 
attributes provided by the exon-2 encoded sequence. 
In some isolates the Tat protein contains additional residues. In these the second exon is 
expanded. In a strain from group O, the MVP5180 isolate, comprises 115 amino acid 
residues. An 86 amino acid form exists for some laboratory-passaged strains, like LAI and 
HXB2, from HIV-1 group M. This variant has been used in many studies and a general map 
of the protein can be made based on this, where the attributes of the protein can be assigned to 
different parts of the protein (figure 1.6). However, since most wild-type strains have 101 
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amino acids, it has been suggested that the 86 amino acid variant represents a truncated non-
natural form of the protein. Most likely it arose as the virus was passaged in tissue culture. 
This postulation is corroborated by the fact that a single nucleotide change in HXB2 and LAI 
at the 87th codon, which in these isolates is a stop codon, results in a 101 amino acid protein 
(Neuveut and Jeang, 1996; Jeang et al, 1999). However, other studies indicate that the 86 
amino acid version does exist in vivo in viruses from subtypes D and H (Kleivbo, 2001). The 
preservation of residues 87-101 in wild-type isolates hints at some biological importance, 
even if they do not contribute significantly to the ex vivo propagation of the virus. 
Furthermore, it has been shown that exon 2 is important in several biological assays 
(Howcroft et al. 1993; Neuveut and Jeang, 1996; Ott et al. 1997; Verhoef et al. 1998; Jeang et 
al, 1999; Col et al., 2002). 
A multiplicity of functions has been ascribed to the Tat protein (Rubartelli et al., 1998). The 
HIV genome is only 9 kbp. This restricts the number of genes and their size, and a possible 
consequence of this is that each HIV-1 protein might have evolved to have multiple functions. 
The different functions and tasks of the Tat protein can be assigned to different domains 
(figure 1.6). These include the proline rich domain, the cystein rich domain, the core domain, 
the basic domain (which is also known as the RNA binding domain) and the glutamine rich 
domain. Also marked are two lysines, 28 and 50. These have been shown to be acetylated by 
HATs, and this modulates Tat’s transactivating properties (Benkirane et. al., 1998). Amino 
acids 78-80 have also been marked. This is the RGD sequence, which is postulated to bind to 
integrins on the cell surface (Valvatne et al., 1996). 
Phosphorylation by PKR, a dsRNA dependent protein kinase, has been suggested to modulate 
Tat function. Differences in the extent to which Tat can be phosphorylated by this protein 
kinase might have an effect on the virulence of the HIV strain (Péloponèse et al., 1999). The 
amino acid residues that are phosphorylated by this kinase have been marked in figure 1.7. 
The most studied region of Tat is the basic domain. It consists of amino acids 49-57, the 
sequence of which is RKKRRQRRR. This is the motif with which Tat binds to TAR (Karn, 
1999). It also functions as a nuclear localization signal, NLS, as well as a nucleolar 
localization signal, NOS. In addition, it seems to be responsible for the uptake of Tat by cells 
(Jeang et al., 1999). The residues flanking this basic domain have been shown to significantly 
influence the specificity of the interaction between Tat and TAR (Karn, 1999). This may be
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the case both for the glutamine rich region as well as the core domain. The core domain has 
along with the first two domains been shown to be necessary for transcriptional function of 
the Tat protein. The cysteine rich domain is thought to bind to the PTEFb complex through 
metal ion binding (Karn, 1999). 
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2 Materials 
2.1 Chemicals 
Chemical name: Supplier: 
2-Mercaptoethanol Merck 
Acetic acid Sigma 
Acrylamide Merck 
Bacto-Agar Difco 
Agarose NA Pharmacia Biotech. 
Ammonium persulphate Biorad 
Ampicillin  Sigma 
Aprotinin Sigma 
Bis-acrylamide Biorad 
Bovine Serum Albumine (BSA) Sigma 
Bromphenol blue IBI 
Chloramphenicol Sigma 
Chloroform Merck 
Chrome sulphuric acid Merck 
Coomassie Brilliant Blue R Sigma 
D(+)-Glucose-Monohydrate Merck 
Diethyl ether Merck 
Dimethyl sulfoxide Merck 
Di-Sodium hydrogen phosphate dihydrate Merck 
Ethanol Arcus Produkter 
Ethylenediaminetetraacetic acid, (EDTA) Sigma 
Ethylphenyl polyethylene glycol, (Nonidet P-40) United States Biochemical corp. 
Ficoll 400 Sigma 
Formic acid Merck 
Gelatine Difco 
Glycerol Merck 
Glycine Merck 
Hydrochloric acid Merck 
Isopropanol Arcus produkter 
Isopropyl-1-thio-β-D-galactoside (IPTG) SERVA 
Kanamycin Sigma 
Leupeptin Sigma 
Magnesium chloride hexahydrate Merck 
Magnesium sulphate Merck 
Methanol Prolabo 
N,N,N’,N’-Tetramethylendiamin, (TEMED) Merck 
PEG 6000 KEBO Lab 
Phenyl methyl sulfonyl fluoride (PMSF) Sigma 
Polyoxyethylene sorbitan monolaurate, (Tween-20) Sigma 
Polyvinylpyrrolidon Merck 
Sodium acetate Merck 
Sodium azide Riedel-De Häen ag. 
Sodium chloride Merck 
Sodium dihydrogen phosphate monohydrate Merck 
Sodium dodecyl sulphate, (SDS) United States Biochemical corp. 
(cont.) 
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Sodium hydroxide pellets Merck 
Trizma base United States Biochemical corp. 
Tryptone Difco 
Yeast extract Difco 
 
2.2 Media solutions and chemicals for cell culturing 
Name: Supplier: 
Foetal Calf Serum (FCS) Bio Whittaker, USA 
Gentamicin Sulphate (50 mg/ml) Bio Whittaker, USA 
Iscove’s Modified Dulbecco’s Medium (IMDM) Bio Whittaker, USA 
Trypsin-Versene mixture Bio Whittaker, USA 
2.3 Cell lines and bacteria 
COS-7 cells 
This cell line stems from the kidney of an African green monkey (Cercopithecus aethiops). 
An origin defective mutant of SV40 has been used to transform these cells, leading them to 
produce the large T antigen. This enables the replication of plasmids containing the SV40 ori. 
E.coli XL1-blue (recA1, endA1, gyrA96, thi, hsdR17 (rk[+], mk[+]), supE44, relA1, [λ][-], 
lac, [F', proAB, lacIqZ[δ]M15, Tn10 (tet[R])]) (Stratagene) 
E.coli DH5α (F- Φ80dlacZ∆M15, ∆(lacZYA-argF)U169, deoR, recA1, endA1, hsdR17(rK-, 
mK+), phoA, supE44, λ-, thi-1, gyrA96, relA1) (Stratagene) 
E. coli BL21 CodonPlus(DE3)-RIL (F- ompT hsdS(rB- m B-) dcm+ Tetr gal λ(DE3) endA The 
[argU ileY leuW Camr]) (Stratagene) 
These latter bacteria were heat shock competent when bought from the supplier, but were 
made electroporation competent for use in the experiments in this thesis. 
2.4 Plasmids 
Plasmid name: Comments: Provider: 
pEGFP-C1 Cloning vector. Expresses the EGFP protein in 
mammalian cell lines. 
Clontech 
pEGFP-Tat72 Expresses a fusion protein in mammalian cell 
lines: The one-exon encoded Tat protein (from 
the HIV-1 strain HXB3) fused to EGFP. 
Vibeke Andresen, MBI, 
UiB, Norway 
pEGFP-Tat86 Expresses a fusion protein in mammalian cell 
lines: The two-exon encoded Tat protein (from 
the HIV-1 strain HXB3) fused to EGFP. 
Vibeke Andresen, MBI, 
UiB, Norway 
(Cont.) 
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pCR-Blunt II-TOPO Cloning vector, used to clone blunt-
ended PCR products. 
Invitrogen. 
pRSET-C Bacterial expression vector. Expresses 
a fusion protein with an N-terminal his-
tag. 
Invitrogen 
LTR-CAT Reporter plasmid. Expresses the CAT 
protein when the LTR promoter is 
activated by Tat protein. 
Vibeke Andresen, MBI, UiB, 
Norway 
Plasmid maps and further information is shown in the appendix (section A.3) 
2.5 Enzymes 
Enzyme: Supplier : 
BamHI Promega 
EcoRI Promega/NEB 
HindIII Promega 
MluI Promega 
XhoI Promega 
Calf Intestinal Alkaline Phosphatase (CIAP) Promega 
T4 DNA Ligase Promega 
RNase A Boehringer Mannheim 
T4 Polynucleotide Kinase Promega 
Pfu Turbo Stratagene 
Taq DNA polymerase Promega 
2.6 Antibodies used in immunofluorescence and Western blot 
Name: Specificity: Host: Dilution: Supplier/reference: 
1D9D5 Tat (aa 2-21)* Mouse 1:10 (WB), undiluted 
(IF) 
Valvatne et al., 1996 
2D9E7 Tat (aa 49-86) Mouse 1:10 Valvatne et al., 1996 
4B4C4 Tat (aa 49-86) Mouse 1:10 Valvatne et al., 1996 
1D2F11 Tat (aa 49-86) Mouse 1:10 Valvatne et al., 1996 
5G7D8 Tat (aa 49-86) Mouse 1:10 Valvatne et al., 1996 
Anti-polyhistidine  his-tag Mouse 1:2000 Sigma 
Anti-CAT CAT Rabbit 1:2000 Sigma 
* The antibody 1D9D5 is reported to have a specificity of amino acids 1-20 of Tat (Valvatne 
et al., 1996). However, the synthetic peptide Valvatne et al. showed that the antibody bound 
to comprises amino acids 2-21 of Tat. 
2.7 Conjugates used in immunofluorescence and Western blot 
Label: Specificity: Method: Dilution: Supplier: 
Horseradish 
peroxidase (POD) 
Mouse WB 1:2000-2500 Amersham 
POD Rabbit WB 1:2000 Amersham 
Alexa568 Mouse IF 1:600 Molecular Probes 
 25 
2.8 Oligonucleotides 
Name: Sequence(5’►3’): Comments: 
Tat115f CGC CTC GAG  CC ATG GAT 
CCA GTA GAT CCT 
TM=60° C XhoI site, used 
to amplify tat115 from the 
pEGFP-Tat115 vector 
Tat115r CGC GAATTC TTA TTG TCC 
TGA GAT CCG TGT AC 
TM=60° C EcoRI site, used 
to amplify tat115 from the 
pEGFP-Tat115 vector 
Tat101f CGC CTC GAG  CC ATG GAG 
CCA GTA GAT C 
TM=60° C EcoRI site, used 
to amplify tat101 from the 
pEGFP-Tat101 vector 
Tat101r CGC GAA TTC TTA ATC GAA 
TGG ATC TGT CTC TGT 
TM=60° C EcoRI site, used 
to amplify tat101 from the 
pEGFP-Tat101 vector 
Primer A GAC GTC TGA TCG G 
GAATTC C ATG GAG CCA 
GTA GAT C 
Used to construct the 
tat101 gene. 
Primer B CTC CAC CTT CTT CTT GGA 
TTC CTT CGG GCC TGT CG 
Used to construct the 
tat101 gene. 
Primer C TCG AAG AAG AAG GTG 
GAG AGA GAG ACA GAG 
ACA GATC 
Used to construct the 
tat101 gene. 
Primer D GGG GGATCC ATC GAA TGG 
ATC TGT CTC TGT CTC TCT 
Used to construct the 
tat101 gene. 
Tatmvp1 CCC AAG CTT CC ATG GAT 
CCA GTA GAT CCT GAG ATG 
CCC CCT TGG CAT CAC CCT 
GGG AGC AAG CCC CAA 
ACC CCT TGT 
Used to construct the 
tat115 gene 
Tatmvp2 CCTT CTT TGT GAA ACA 
AAC ATA GCA ATG ATA 
GCA GCA TCT TTT GCA ATA 
GCA ATT ATT ACA AGG GGT 
TTG GGG CTT 
Used to construct the 
tat115 gene 
Tatmvp3 ATGTT TGT TTC ACA AAG 
AAG GGT TTG GGA ATC TCC 
CAT GGC AGG AAG AAG 
CGA AGA AGA CCA GCA 
GCT GCT GCA AGC 
Used to construct the 
tat115 gene 
Tatmvp4 TT CCT GCC GGT GTG GGA 
CAG GGA TTG CTC TGG TAC 
AGG ATC TTT ATT ATC TGG 
ATA GCT TGC AGC AGC TGC 
TG 
Used to construct the 
tat115 gene 
Tatmvp5 TCC CAC ACC GGC AGG 
AAG CAG AAA CGC CAG 
GAA GAA CAG GAG AAG 
AAG GTG GAG AAG GAG 
ACA GGC CCA AGT GGA C 
Used to construct the 
tat115 gene 
 
 
 
(Cont.) 
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Tatmvp6 CCC GGA TCC TTG TCC TGA 
GAT CCG TGT ACA ACT GTT 
GCA AGA ATC CTG GTG 
GCA AGG CTG TCC AG*T 
TGG GCC TGT C 
Used to construct the 
tat115 gene 
Tatmvpa CCC AAG CTT CC ATG GAT 
CCA GTA G 
TM=56°C, used to amplify 
the tat115 gene 
Tatmvpb CCC GGATCC TTG TCC TGA 
GAT CC 
TM=56°C, used to amplify 
the tat115 gene 
Written in italics are restriction enzyme cutting sites. Written in bold are start and stop 
codons. Written in bold and marked with an asterisk is one nucleotide in the Tatmvp6 
oligonucleotide. This one nucleotide erroneously replaces a C, and makes the sequence of the 
tat115 gene differ from the tat gene from MVP5180. 
2.9 Commercial reagents 
Name: Supplier: 
Big DyeTM Terminator (Terminator Ready 
Reaction Mix) 
Perkin Elmer Applied Biosystems, USA 
6X Loading dye Promega 
dNTP Promega 
2.10 Molecular weight markers 
Name: Supplier: 
Lambda/HindIII digest Promega 
pGEM Markers Promega 
Prestained Broad Range Standard NEB 
Kaleidoscope markers Biorad 
2.11 Instruments, computers and software 
Amersham pharmacia biotech Hyperfilm Autoradiography film  
ASSAB CO2 incubator  
Bachofer Speed Vac Concentrator  
Beckman CPR centrifuge 
Beckman GS-15R Centrifuge 
Bender & Hobein AG Vortexer Model K-550-GE  
Biorad Mini-PROTEAN 3 Acrylamide gel equipment  
Biorad Power supply Model 200/2.0 
Biorad Mini Trans-blot Cell blotting equipment  
Biorad Gene Pulser ® Cuvette Electroporation cuvettes  
Biorad Gene Pulser Electroporator  
Biorad Pulse Controller 
Biorad Gene Pulser II 
Biorad Gene Pulser II RF module 
Centrifuge A 14 Eppendorf centrifuge Jouan  
Clifton heater (Alfa-lab A/S) 
Costar minicentrifuge 
(Cont.) 
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EC575 and EC105 Voltagesupplier (E-C Apparatur corporation) 
Fedegari autoclave (Max Planck Institut) 
Fuji X-ray film developer RGII 
GeneAmp PCR System 2400 thermocycler (Perkin Elmer) 
Gilson Pipettes: 0.1-2 µl, 2-20 µl, 20-100 µl, 50-200 µl, 200-1000µl  
Heigar weight (Precision standard) 
Heraeus incubator (Max Planck Institut) 
HorizonTM58 Gel electrophoresis system (Bethesda Research Laboratory) 
HT Incubator with shaking Infors AG  
Kontes Micro Ultrasonic Cell Disrupter  
Leica DM Irbe fluorescence microscope 
Mettler weight AJ100 
Microwave oven  
MiliQ-plus (Millipore) 
Multiscan MS ELISA-plate reader Labsystems  
Owl Separation Systems Inc. Model B1 Agarose gel equipment 
Radiometer Copenhagen pH-system  
Savant SpeedVac SVC100 Vacuum centrifuge  
Shimadzu UV-1201 uv-vis spectrophotometer  
Sigma Laboratory centrifuge GmbH model 112 
Sorvall RC5B Refrigerated Superspeed Centrifuge  
Sorvall RC-53 centrifuge (DuPont Instruments), rotors: SS-34, GSA, HB-4 
Techne dri-block DB1 and DB2a (HOUM A/S) 
Temaks incubator 
Thermomixer compact JOUAN A14 (Eppendorf) 
Whatman Chromatography paper 3MM Chp Filterpaper 
FPLC System (Pharmacia): 
Monitor UV-1 
P-500 pumps 
Controller 
LCC-500 
LCC-500 plus 
Fraction collector Frac-100 
Valve MV-7 
Mixer 
Peristaltic pump P-1 
1 ml HiTrap Chelating column  
IBM compatible PC, OS/2 
FPLC Director Software 
Computers: 
Apple MacIntosh Computer 
Leica DM IRBE linked to a MacIntosh Computer. The Openlab program was used for image 
capturing. 
IBM Compatible PC, Windows OS 
Software: 
Microsoft Office 
Image Editing programs: 
Adobe Photoshop 7.0 
Adobe Illustrator 9.0 
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2.12 Commercial kits 
Name: Supplier: 
Qiagen Plasmid Mega kit Qiagen, USA 
Qiaex II Gel extraction Kit Qiagen, USA 
Slow FadeTM Antifade kit Molecular Probes, USA/Holland 
ECLTM Western blotting detection reagents, 1 and 2 Amersham Pharmacia 
Concert Rapid Miniprep Gibco BRL Life Technologies 
Concert rapid gel extraction Gibco BRL Life Technologies 
Concert Rapid PCR purification system Gibco BRL Life Technologies 
2.13 Consumables 
Name: Size: Supplier: 
Nunc Easy Flask 25 cm2 
75 cm2 
NUNC Brand Products, Nunc 
A/S, Denmark 
NunclonTM Multidishes 6 wells 
24 wells 
NUNC Brand Products, Nunc 
A/S, Denmark 
Transfer pipette 3.5 ml Sarsted 
High performance 
Chemoluminesence film 
HyperfilmTM ECLTM 
 Amersham Life Science, UK 
Microscope slides 76 X 26 mm Merck 
Microscopical cover-glasses 12 mm Assistent 
Millipore Express sterile filter 0.22 µm Millipore 
FP30 sterile filter 0.45 µm Schleicher & Schuell 
Nitrocellulose transfer 
membrane 
300 mm X 3 m, 0.45 µm Schleicher & Schuell 
2.14 Buffers and solutions:  
Buffer/Solution: Recipe: 
30% Acrylamide/bis 291 g Acrylamide 
9 g Bis-acrylamide 
1 liter dH2O 
Agarose gel (1%) 1% (w/v) Agarose in TAE-buffer (1X) with 
0.5 µg/ml EtBr  
10% Ammonium Persulphate (APS) 0.1 g Ammonium Persulphate 
dH2O was added to 1 ml 
Blocking solution 1 g Ficoll 
1 g Polyvinylpyrrolidone 
10.3 g Boric acid  
1.1 g NaOH 
8.8 g NaCl 
1 ml Nonidet P-40 
0.5 g Gelatin 
15 g BSA (Bovine serum albumine) 
dH2O was added to 1 l. 
10 X blotting buffer 144 g Glycine 
30.3 g Trizma base 
dH2O was added to 1 liter 
(Cont.) 
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1 X blotting buffer 7 parts of dH2O 
2 parts of Methanol 
1 part of 10X blotting buffer 
BSA (0.5%) - blocking buffer: 0.5 g Bovine serum albumine 
100 ml PBS 
Buffer A (for FPLC) 100 mM NaCl  
50 mM Na2HPO4  
pH 8.0 (adjusted with NaOH and HCl) 
The buffer was sterilised by filtration. 
Buffer B (for FPLC) 100 mM NaCl  
50 mM NaH2PO4  
pH 4.0 (adjusted with NaOH and HCl) 
The buffer was sterilised by filtration. 
Coomassie blue staining solution 40% (v/v) EtOH,  
10% (v/v) HAc and  
0.1% (w/v) Coomassie Brilliant Blue R  
in dH2O 
De-staining solution: 10% Acetic acid 
10% Methanol  
in dH2O 
Ethidium bromide solution (EtBr) 0.5 mg/ml Ethidium bromide in dH2O 
Frozen Storage Buffer (FSB) Stock Solution 
GTE-buffer 50 mM Glucose 
25 mM Tris-Cl, pH=8.0 
10 mM ETDA, pH=8.0 
Sterilized by autoclaving 
GYT buffer 10 ml 10% Glycerol 
0.125 g Yeast extract 
0.250 g Tryptone 
dH2O was added to 100 ml 
Sterilized by autoclaving 
2 x HBS 8.0 g NaCl 
6.5 g HEPES (sodium salt) 
10 ml 1.0 M Na2HPO4 (Merck) 
The pH was adjusted with NaOH and HCl to 
7.0. The volume was adjusted with dH2O to 
500 ml, and the buffer was sterilised by 
filtration. 
Hypotonic buffer (lysis buffer) 10 mM Tris-Hcl pH 7.4 
10 mM NaCl 
1.5 mM MgCl2 
0.5% NP-40 
(Cont.) 
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LB medium: 5 g NaCl 
5 g Yeast extract 
10 g Tryptone 
1 ml 1 M NaOH 
dH2O was added to 1 liter 
Sterilized by autoclaving 
Added if required: 
Antibiotics 
15g Bacto agar (for generation of agar plates.) 
1x PBS, per liter dH2O: 8 g NaCl 
0.2 g KCl 
1.81 g Na2HPO4 x 2H2O (or 1.44 g Na2HPO4) 
0.24 g KH2PO4 
pH was adjusted to 7.4 with 1 M HCl. 
13% PEG 6000 13% PEG 6000 (w/v) in dH2O 
Sterilized by autoclaving 
4% PFA (Paraformaldehyde)-solution 1 g PFA in 25ml PBS 
100 mM PMSF 17.4 mg/ml in Isopropanol 
Potassium acetate (3M), pH~5.5: 3 M KAc 
1.18 M Formic acid in dH2O 
4 x Sample buffer: 2 ml 0.5 M Tris-HCl pH 6.8  
1.6 ml Glyserol 
3.2 ml 10% SDS 
0.8 ml Mercaptoethanol 
0.4 ml 0.1% Bromphenolblue 
0.4 ml 0.01% Pyronin B 
SOB 10 g Tryptone 
2.5 g Yeast extract 
0.29 g NaCl (10 mM) 
0.093 g KCl (2.5 mM) 
Sterilized by autoclaving 
SOC 0.5 ml 1 M MgCl2 
0.5 ml 1 M MgSO4 
0.5 ml 2 M Glucose 
SOB medium till 50 ml 
Sucrose buffer 27 mM Na2HPO4 
150 mM Sucrose 
Sterilized by autoclaving 
Separating gel (20% acrylamide): 6.7 ml 30% (w/v) Acrylamide/0.8% (w/v) 
Bis-acrylamide in dH2O 
2.5 ml 4xTris-Cl, pH 8.8 
0.6 ml dH2O 
100 µl 10% SDS (Sodium Dodecyl Sulphate) 
Immediately before casting the following was 
added: 
50 µl 10% (w/v) ammonium persulfate (fresh) 
10 µl TEMED 
(Cont.) 
 31 
Stacking gel solution, 2 gels 3.05 ml dH2O 
1.25 ml 0.5 M Tris-HCl, pH 6.8 
50 µl 10% SDS 
0.65 ml 30% Acrylamide/bis  
Immediately before casting the following was 
added: 
25 µl 10% APS 
5 µl TEMED 
10 x Running buffer (for SDS-PAGE) 18 g Trizma base 
86.4 g Glycin 
60 ml 10% SDS 
3M Sodiumacetate, pH 4.8 40.81 g Sodium acetate 
80 ml H2O 
pH was adjusted to 4.8 with glacial acetic acid 
dH2O was added to 100 ml 
1X TAE: 40 mM Tris-acetate 
1 mM EDTA 
TB (Terrific Broth) 12 g Tryptone 
24 g Yeast extract 
4.0 ml Glycerol 
dH2O was added to 900 ml 
Sterilized by autoclaving 
100 ml of the following autoclaved buffer was 
added: 
0.17 M KH2PO4 (2.38 g/100 ml) 
0.72 M K2HPO4  (12.4 g/100 ml) 
10 x TBS 200 ml 1 M Tris-HCl, pH 7.5 
300 ml 5 M NaCl 
500 ml dH2O 
The medium was autoclaved. 
TBS-Tween: 100 ml 10 x TBS 
500 µl Tween-20  
900 ml dH2O 
TE-buffer  (1X): 10 mM Tris-Cl, pH=8.0 
1 mM EDTA, pH=8.0 
0.5 M Tris-HCl, pH 6.8 60.6 g Trizma base  
1 l dH2O 
pH was adjusted to 6.8 with 1 M HCl 
1.5 M Tris-HCl, pH 8.8 181.7 g Trizma base 
1 l dH2O 
pH was adjusted to 8.8 with 1 M HCl 
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3 Methods 
3.1 Gene cloning techniques 
3.1.1 The PCR reaction 
The Polymerase Chain Reaction is a method for amplification of DNA. It is based on cyclical 
temperature variation. Each cycle starts with the reaction mixture being heated so that the 
strands of the DNA to be copied, the template, break apart (denaturation). This is followed by 
a lower temperature where a pair of small oligonucleotides anneals to the template DNA. 
These oligonucleotides are designed such that one of them, the forward primer, is similar to 
the 5’ end of the sequence, and thus binds to the 3’ end of the reverse strand. The other 
oligonucleotide, the reverse primer, is similar to the reverse strand at the end of the sequence 
to be amplified. Thus it binds to the 3’ end of the sequence on the first strand. The cycle 
continues with a temperature optimal for a DNA polymerase to elongate the oligonucleotides 
from the 5’ end to the 3’ end (elongation). The elongation of these oligonucleotides is then 
based on the sequence of the template DNA. The oligonucleotides of one type that are 
elongated in each cycle can be used as template for the other type of oligonucleotide in the 
subsequent cycles. Thus with each cycle the amount of product/template can theoretically be 
doubled. In the reaction one uses a thermostable DNA polymerase, able to withstand the 
temperature needed to denature the template DNA. Most commonly used is the Taq 
polymerase. 
The temperatures used in the PCR cycle are rarely altered when it comes to the denaturation 
temperature (which is commonly 94° C), and the elongation temperature (which is commonly 
72° C). However the annealing temperature is usually varied. This is done according to the 
calculated melting temperature, TM, of the stretch where the oligonucleotides overlap with the 
template. A simple formula used to calculate the melting temperature is: 
TM=[4*(G+C)+2*(A+T)]° C 
A is the number of Adenines, T is the number of thymines, C is the number of cytosines and 
G is the number of guanines in the part of the oligonucleotide that overlaps with the template. 
The annealing temperature is then given as TM-5° C. 
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Figure 3.1: Schematic view of a PCR program showing how the temperature in the reaction mixture is varied with time. 
There are 4 main phases: An initial heating to denature the DNA, then the cycle, then a final elongation step, before cooling 
at 4° C pending further work. The cycle is usually repeated 25-35 times, and consists of a denaturation step, where the 
temperature is optimal for separating the DNA strands of the template, an annealing step, where the temperature is optimal 
for hybridisation between the oligonucleotides and the template DNA, and an elongation step, where the temperature is 
optimal for the thermostable DNA polymerase to elongate the oligonucleotides. 
3.1.2 Amplification of genes by PCR 
The tat101 and tat115 genes were amplified by PCR from the EGFP-vectors containing them. 
The reaction mixture was as follows: 
DNA template (50 ng/µl) 10 µl  
10X PCR buffer 10 µl  
10 mM dNTP 4 µl 
Primers (1µg/µl) 2 µl of each  
Taq DNA Polymerase (5 U/µl) 1 µl 
dH2O 78 µl 
Total volume 100 µl 
The DNA template used were the EGFP-Tat plasmids diluted in dH2O. The EGFP-Tat101 
plasmid and the Tat101F and Tat101R primers were used when the tat101 gene was 
amplified. The EGFP-Tat115 plasmid and the Tat115F and Tat115R primers were used when 
the tat115 gene was amplified. The reaction cycle was as follows: 
 
Initial denaturation step 94° C 7 min 
Cycle:    
Denaturation 94° C 30 sec 
Annealing 59 (+0.2 per cycle) ° C 30 sec 
Elongation 72° C 2 min 30 sec 
Repeat cycle 35 times   
Final extension step 72° C 8 min 
Cooling 4° C ∞ 
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A similar reaction was also used to remove the 3’ T added by the Taq polymerase from the 
amplified tat115 gene. The polymerase used was then Pfu Turbo, the template was the 
amplified tat115 gene, and the primers were Tat115f and Tat115r. 
3.1.3 Addition of nucleotides to the 3’ end of a gene by PCR 
In one PCR reaction the original gene is amplified. The reverse primer used in this reaction is 
made such that a small part is added to the gene. This will ensure that this PCR product is 
overlapping with a different PCR product that is generated in another reaction. In this other 
PCR reaction the sequence to be added is made by two oligonucleotides that are overlapping. 
These two PCR products are then used as template in a third PCR reaction. Seeing how they 
partially overlap they will in the first cycles generate the new gene. In the later cycles the final 
product is amplified by the forward primer from the first PCR reaction and the reverse primer 
from the second PCR reaction. A schematic view of this is shown in figure 3.2. This 
procedure was used to create the tat101 gene, by adding nucleotides encoding the last 15 
amino acids of the Tat101 protein to the tat86 gene.  
For the two parallel PCR reactions the reaction mixture was as follows: 
DNA template (50 ng/µl) 10 µl  
10X PCR buffer 5 µl 
10 mM dNTP 2 µl 
Primers (0.2 µg/µl) 2.5 µl of each 
Taq DNA Polymerase (2.5 U/µl) 0.5 µl 
dH2O 22.5 µl 
Total volume 50 µl 
In one of the reactions, the DNA template was the EGFP-Tat86 plasmid, and the primers used 
were Primer A and Primer B (section 2.8). In the other reaction the primers used were primer 
C and Primer D, and no DNA template was used. In this reaction 32.5 µl dH2O was used. The 
reaction cycle was as follows: 
Initial denaturation step 94° C 5 min 
Cycle:    
Denaturation 94° C 90 sec 
Annealing 55 ° C 2 min 
Elongation 72° C 3 min  
Repeat cycle 7 times   
Cooling 4° C ∞ 
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The generation of the tat101 gene was completed by using the products of these two PCR 
reactions as template in a new PCR reaction. In this the reaction mixture was as follows: 
Template 1 µl of each of the two preceding reactions 
10X PCR buffer 5 µl 
10 mM dNTP 1 µl 
Primers (0.2 µg/µl) 5 µl of each 
Taq DNA Polymerase (2.5 U/µl) 0.5 µl 
dH2O 31.5 µl 
Total volume 50 µl 
The primers used were Primer A and Primer D. The reaction cycle was as follows: 
Initial denaturation step 94° C 5 min 
Cycle:    
Denaturation 94° C 90 sec 
Annealing/ Elongation 72° C 5 min 
Repeat cycle 25 times   
Final extension step 72° C 7 min 
Cooling 4° C ∞ 
 
 
Figure 3.2: A schematic view of how the tat101 gene was synthesized. A black arrow indicates the product of a PCR 
reaction, while a grey arrow indicates that this product was used as a template in a new PCR reaction. 
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3.1.4 Constructing a synthetic gene b
 to be studied is not available, a 
The tat115 gene was made with this technique. 
y PCR  
If the gene
synthetic version of the gene can be 
constructed. This is also a practical option if 
the gene needs to be mutated so extensively 
that site-directed mutagenesis would be a time-
consuming process. The gene can be made by 
oligonucleotides that are overlapping. The 
oligonucleotides represent the gene in its 
entirety, but only partially each strand. The 
double stranded gene is then synthesized in a 
PCR reaction (Dillon and Rosen 1990; 
Prodromou and Pearl 1992; Sandhu et al. 
1992; Stemmer et al., 1995). Overlapping 
nucleotides from each strand form 
successively larger products with each PCR 
cycle. In the end they will produce the entire 
gene, which will then be amplified by flanking 
primers. The principle of how the gene is 
gradually constructed with each cycle of the 
reaction is shown in figure 3.3. 
In a first PCR reaction the gene was generated 
using the primers called Tatmvp1-6. The 
reaction mixture was as follows: Fig 3.3: The principle of gene construction by PCR. This
technique was used to construct the tat115 gene. Separate
large overlapping oligonucleotides are mixed, and this
figure shows the intermediate products after the first,
second and third cycle in a hypothetical experiment where
6 oligonucleotides together hold the entire genetic
sequence. After the final product has been formed (after
the third PCR cycle), this is amplified with a set of
smaller outer primers.  
10X PCR buffer 5 µl 
/µl) f each 
e (2.5 U/µl) 
 
10 mM dNTP 1 µl 
Primers (0.2 µg 1 µl o
Taq DNA Polymeras 0.5 µl 
ddH2O 37.5 µl
Total volume 50 µl 
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And this reaction mixture was used in the following reaction cycle: 
Initial denaturation step 94° C 7 min 
Cycle:    
Denaturation 94° C 90 sec 
Annealing 55 ° C 2 min 
Elongation 72° C 3 min 
Repeat cycle 7 times   
Final extension step 72° C 3 min 
Cooling 4° C ∞ 
The gene was then amplified in a new PCR reaction, where the product of the previous PCR 
reaction was used as a template, and the Tatmvpa and Tatmvpb primers were used. The 
reaction mix was as follows: 
Template 1 µl  
10X PCR buffer 10 µl 
10 mM dNTP 4 µl 
Primers (0.2 µg/µl) 5 µl of each 
Taq DNA Polymerase (2.5 U/µl) 1 µl 
dH2O 64 µl 
Total volume 100 µl 
And the PCR program was as follows: 
Initial denaturation step 94° C 5 min 30 sec 
Cycle:    
Denaturation 94° C 1 min 30 sec 
Annealing/Elongation 72° C 5 min 
Repeat cycle 30 times   
Final extension step 72° C 2 min 
Cooling 4° C ∞ 
3.1.5 The construction of the EGFP-Tat101 and EGFP-Tat115 plasmids 
The flanking primers that were used to construct the tat genes (sections 3.1.3 and 3.1.4) had 
been designed so that the final products of these PCR reactions had restriction enzyme sites at 
the ends. These restriction enzyme sites had been chosen so that it would be easy to clone the 
genes into the MCS of the EGFP-C1 plasmid. Additional nucleotides had been added between 
the restriction enzyme sites and the tat genes so that the genes would be in frame with the 
gene encoding EGFP, and an EGFP fusion protein would be generated. The enzymes that 
were chosen were HindIII and BamHI for tat115 and EcoRI and BamHI for tat101. The PCR 
products were treated with these restriction enzymes (section 3.1.9). After this they were 
purified (section 3.1.10), to remove anything in the reaction that could interfere with the 
ensuing enzymatic reactions. The plasmid pEGFP-C1, in which these restriction enzyme sites 
were unique, was also treated with these enzymes. The plasmid was also treated with a 
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phosphatase (section 3.1.12) in order to prevent it from re-ligating later, and purified by gel 
extraction (section 3.1.11). This would hinder any uncut plasmid from being present in the 
ligation mixture that would be used to transform bacteria. The genes were then ligated into the 
plasmid in separate reactions (section 3.1.13).  
Bacteria were then transformed with a few µl of these ligation reactions (sections 3.1.17 and 
3.1.18). The pEGFP-C1 plasmid and the expected derivatives of it would confer resistance to 
kanamycin, so this antibiotic was used in the process of selecting for these plasmids in these 
procedures. Bacteria that survived the selection process in the transformation procedure were 
then grown in 5 ml LB or TB medium, and analysed by miniprep (section 3.1.19). The 
purified plasmid from these was then checked to see if it was correct by restriction enzyme 
analysis. This analysis was performed by cutting the plasmid with the restriction enzymes that 
had been used when the insert was ligated into the vector. So the assumed EGFP-Tat115 
plasmid was cut with BamHI and HindIII, while the assumed EGFP-Tat101 plasmid was cut 
with EcoRI and HindIII. If a DNA piece of the expected size were excised when both 
enzymes were used and not when only one enzyme was used then that would indicate that the 
correct gene had been inserted into the vector. A few µl of these reactions were then run on 
agarose gels to visualize the results.  
Purified plasmid in which the appropriate gene seemed to have been inserted was used in 
DNA sequencing to verify that the insert had the correct sequence (section 3.1.22). A culture 
from which a such plasmid had come was then used in the Qiagen Megaprep protocol to 
purify large amounts of this plasmid (section 3.1.20). The identities of the plasmids that were 
purified with this procedure were then established by restriction enzyme analysis. 
3.1.6 The construction of the pRSET-Tat101 plasmid 
In order to clone the tat101 and tat115 sequences into the bacterial expression vector pRSET-
C, these genes were amplified by PCR as described in section 3.1.2. The constructed EGFP-
Tat plasmids were used as template, and the primers used were Tat101f and Tat101r, for the 
amplification of tat101; and Tat115f and Tat115r for the amplification of tat115 (section 2.8).  
When it came to the construction of the pRSET-Tat101 plasmid, the procedure was very 
much like the one described in section 3.1.5. The PCR product containing the tat101 gene was 
purified (section 3.1.10), treated with the appropriate restriction enzymes (section 3.1.9), 
purified again and ligated (section 3.1.13) into the pRSET-C plasmid, that had been digested 
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with the same restriction enzymes and treated with phosphatase (section 3.1.12). Then this 
ligation mixture was used to transform bacteria (sections 3.1.17 and 3.1.18), plasmid was 
purified from these bacteria (3.1.19), and the plasmid was subjected to restriction enzyme 
analysis. Plasmids in which the correct bands were excised were sequenced (section 3.1.22), 
and the plasmid containing the correct product was purified by megaprep (3.1.20). Afterwards 
the identity of this plasmid was verified by restriction enzyme analysis. 
3.1.7 The construction of the pRSET-Tat115 plasmid 
The PCR product containing the tat115 gene was subcloned into a TOPO vector, pCR-
BLUNT II-TOPO. This vector requires the insert to be blunt ended. The PCR product with the 
tat115 gene was originally amplified with Taq DNA polymerase, which leaves a 3’ T 
overhang. To get a blunt PCR product the original PCR product was amplified in a new PCR 
reaction using the Pfu Turbo DNA polymerase (section 3.1.2). The PCR product from this 
reaction was ligated into the TOPO vector (section 3.1.14), and the gene was cut out of the 
plasmid using the XhoI and EcoRI enzymes (section 3.1.9), and purified by gel extraction 
(section 3.1.11). However, the vector also contained these restriction enzyme sites, and not 
too far from the sites that were placed outside the gene by the primers (although on opposite 
sides). So when the gene was purified from the vector by gel extraction, some not completely 
digested fragments could contaminate the fragment that was to be ligated into the pRSET-C 
vector. This was checked for in the screening of colonies by looking for fragments that were 
cut out of the vector with only one of the restriction enzymes. A colony with the correct insert 
was then used to purify the plasmid with an alkaline lysis midiprep procedure (section 3.1.19). 
The gene was then cut out of this plasmid with EcoRI and XhoI enzymes, and purified by gel 
extraction. The purified gene was then ligated into the pRSET-C vector, in a similar manner 
as when this was done with the tat101 gene (section 3.1.6). Figure 4.9 shows the restriction 
enzyme analysis of the plasmid preps generated in this procedure. When DNA sequencing of 
the minipreps affirmed the identity of the plasmid, an alkaline lysis midiprep procedure was 
used to purify the plasmid.  
3.1.8 Agarose gel electrophoresis 
The PCR products, as well as plasmids digested with restriction enzymes, were analysed by 
agarose gel electrophoresis. The gels contained 1-2% agarose, 1xTAE-buffer, as well as 0.5 
µg/ml EtBr, for the later visualization of the DNA.  The gels were run in 1x TAE-buffer.  The 
gels were typically 10 cm long, and electrophoresis was performed for 30 minutes to 2 hours 
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at 100-200 V. The time varied with the resolution required. Visualization was done by UV-
light. 
3.1.9 Restriction enzyme digestion of DNA 
Restriction enzymes recognize specific sequences of DNA and cleave the DNA at this 
vicinity. Enzymes and buffers provided by Promega and NEB were used. The volume used 
for a restriction enzyme digest was usually 20 µl. The DNA was diluted in dH2O, the buffer 
that was supplied with the restriction enzyme was added, and typically 5-10 U restriction 
enzyme was added. The mix was incubated at 37° C for one hour, or over night. To avoid the 
restriction enzymes interfering in the reactions that followed, the DNA was purified. The 
purification of DNA was then done either by gel extraction or by the PCR purification kit. 
An example of a restriction enzyme digest with two enzymes: 
DNA (5µg/µl) 1 µl 
Enzyme 1 (10 U/µl) 1 µl 
Enzyme 2 (10 U/µl) 1 µl 
10X multicore buffer 2 µl 
dH2O 15 µl 
Total volume 20 µl 
3.1.10 Purification of PCR products and removal of restriction enzymes 
The Concert Rapid PCR Purification kit was used in accordance with the manufacturer’s 
protocol to purify PCR products. This kit was also used to purify these PCR products after 
they had been digested with restriction enzymes. 
3.1.11 Purification of DNA by extraction from gel 
The Concert Rapid Gel Extraction kit was used to purify plasmid DNA. This was done when 
the DNA had been treated with restriction enzymes and a phosphatase. The manufacturer’s 
protocol was followed. 
3.1.12 Phosphatase treatment of digested DNA 
A phosphatase is used to remove the 5’ phosphate group of a DNA fragment. In this study this 
was routinely done with plasmids that had been digested with restriction enzymes to prevent 
re-ligation of the plasmid in subsequent ligation reactions. A typical reaction mixture was as 
follows: 
Digested plasmid solution 20 µl 
Phosphatase (CIAP 1U/µl) 1 µl 
10X phosphatase buffer 3µl 
dH2O 6 µl 
Total volume 30 µl 
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The mixture was incubated at 37° C for 30 minutes, then the plasmid was purified by gel 
extraction. 
3.1.13 Ligation of DNA fragments 
In a ligation reaction a DNA ligase chemically couples two DNA ends, the 5’ and 3’ ends. It 
can ligate so-called blunt ends or staggered ends. In this study this was used to ligate inserts 
into plasmids. The inserts were most often PCR products that had been digested with 
restriction enzymes. The plasmids had been treated with restriction enzymes that would 
render the same staggered ends as the ones used to digest the PCR products. The insert and 
plasmid DNA was added in amounts corresponding to a ratio of 3:1, 1:1, or 1:3. This was 
estimated by running both fragments on agarose gels for comparison of the relative molar 
amounts. Ligation buffer, ligase enzyme and dH2O were added to a total volume of 10-30 µl, 
and the ligation mix was incubated over night at room temperature. An example of a ligation 
reaction mix, where the plasmid contains about 15 times as many base pairs as the insert: 
Plasmid (50 ng/µl)  2 µl 
Insert (2 ng/µl) 3.5 µl 
10X Ligase buffer 1 µl 
T4 DNA ligase (1 U/µl) 0.3 µl 
dH2O 3.2 µl 
Total volume 10 µl 
3.1.14 TOPOTM Cloning 
The Zero BluntTM TOPOTM PCR Cloning kit from Invitrogen is used to clone blunt-end PCR 
products. The pCR-Blunt II-TOPO vector is supplied linearized with vaccinia virus 
topoisomerase I covalently bound to the 3’ end. This means that ligation with a blunt-end 
PCR product will occur spontaneously. A PCR product containing the tat115 gene was cloned 
this way. The manufacturer’s protocol was followed. 
3.1.15 Electrocompetent cells 
The bacteria used in this procedure were E. coli BL21 CodonPlus(DE3)-RIL from Stratagene. 
These bacteria were originally heat shock competent. The bacteria were streaked out on a 2x 
YT-G agar plate containing 25 µg/ml chloramphenicol (this antibiotic and this concentration 
of it is used in the media throughout the procedure), and were incubated at 37°C O/N. One 
colony was then picked to inoculate 5 ml 2xYT-G media, which was then incubated at 37°C 
O/N. 2.5 ml of this culture was then transferred to 1 litre of 2x YT-G media, and this was 
grown at 37°C until the OD600 reached ~0.6, at which point the culture was cooled on ice for 
30 minutes. The bacteria were then harvested in 4 GSA tubes by centrifugation at 4000 g for 5 
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minutes at 4°C. From this point on the bacteria were kept on ice at all times. The supernatant 
was discarded, and each pellet was resuspended in 100 ml of ice-cold 10% glycerol. The 
resuspended bacteria were divided between two GSA tubes, and the centrifugation was 
repeated. Each of the two pellets was then resuspended in 100 ml ice-cold 10% glycerol, and 
the centrifugation was repeated. Each bacteria pellet was then resuspended in 2 ml GYT 
media, and 50 µl aliquots were put in eppendorf tubes. The aliquots were then flash-frozen on 
dry ice in ethanol, before they were stored at -80°C until they were to be used. 
3.1.16 Heat shock competent cells 
One colony of E.coli DH5α Bacteria was grown over night (o/n) at 37°C in SOB-medium 
with 20 mM MgSO4. From this culture 2 ml was added to 100 ml of the same medium, and 
this was incubated at 37°C until the A600 was ~ 0.4 - 0.6. The bacteria were transferred to four 
pre-chilled 50 ml centrifuge-tubes and incubated on ice for 10 min. They were then harvested 
by centrifugation at 1500 g for 10 min at 4°C. The pellets were then resuspended in 15 ml ice-
cold FSB-buffer and incubated on ice for 10 min before another centrifugation at 1500 g for 
10 minutes. Each pellet was resuspended in 2 ml FSB and 70 µl DMSO was added. This mix 
was then incubated on ice for 15 min before 100 µl aliquots of it was added to eppendorf 
tubes. These tubes were then flash-frozen on dry ice in ethanol. 
3.1.17 Transformation by electroporation 
Plasmid DNA (from a few ng up to 1 µg) was mixed with 40 µl of electro-competent cells. 
This mixture was then transferred to a pre-chilled electroporation cuvette, which was then 
placed in an electroporator (Biorad Gene Pulsar). A pulse of 2.5 kV was applied, 1 ml of 
SOC-medium was added to the mixture which was then transferred to a sterile eppendorf-tube 
and incubated for approximately 45 minutes at 37°C with moderate shaking. Subsequently 50 
µl of the culture was plated out on a LB-plate containing the appropriate antibiotics for 
selection of bacteria containing the plasmid. The rest of the bacteria were harvested by 1 
minute of centrifugation at 13000 rpm in a Sigma laboratory centrifuge (model 112), the 
supernatant was poured of, and the pellet was re-dissolved in 100 µl SOC-medium and this 
was plated out on another LB-plate containing the same antibiotics. The plates were incubated 
at 37°C over night. 
3.1.18 Transformation by heat shock 
1-100 ng plasmid was added to and mixed with 50 µg heat-shock competent bacteria. This 
was then incubated on ice for 30 min. The mixture was then incubated at 42°C for 60-90 
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seconds and put directly on ice for 2 min. 1 ml SOC-medium was added and the bacterial 
suspension was incubated on a shaker at 37°C for approximately 45 min. The suspension was 
transferred to LB-plates containing the proper antibiotics, just as in the procedure for 
electroporation. 
3.1.19 Small-scale preparations of plasmid DNA 
The alkaline lysis/PEG method 
This procedure was used for detection and characterization of plasmids. All centrifugations in 
this procedure, except for the vacuum centrifugation, were done at 13000 rpm in a table 
centrifuge. One single bacterial colony was scraped from an LB-plate and inoculated into 5-
10 ml of TB-medium containing the appropriate antibiotic, and grown to saturation over night 
at 37°C with moderate shaking. 4.5 ml (1.5 ml of the culture three times) of the culture was 
spun down for 1 minute in a Sigma laboratory centrifuge and the supernatant removed. The 
pellet was resuspended in 200 µl GTE-solution by pipetting up and down. 300 µl of 0.2 M 
NaOH/1% SDS solution was added, the solution was mixed by inverting the tube a few times, 
and the tube was placed on ice for 5 minutes. Subsequently, 300 µl of KAc-solution was 
added. The mixture was vortexed and placed on ice for 5 minutes, before centrifugation for 10 
minutes in a Sigma laboratory centrifuge to pellet cell debris and chromosomal DNA. The 
supernatant was transferred to a clean eppendorf tube, RNase A was added to a final 
concentration of 20 µg/ml, and this was incubated for 20 minutes at 37°C. The supernatant 
was extracted with chloroform, 400 µl chloroform was added to the tube and this was 
vortexed for 30 seconds before centrifugation for 1 minute, the top aqueous phase was then 
transferred to a clean tube. The chloroform extraction was repeated until there was no debris 
visible between the organic and aqueous phases (In other words this chloroform extraction 
was done at least twice, some times thrice). The DNA was then precipitated by the addition of 
an equal volume of 100% isopropanol, this was swiftly mixed before it was centrifuged for 10 
minutes at room temperature. The supernatant was removed, the pellet was washed with 500 
µl 70 % ethanol, the tube was centrifuged for two minutes, the ethanol was decanted, and 
subsequently the pellet was dried in a vacuum centrifuge for 10 minutes. The pellet was then 
dissolved in 32 µl of deionized H2O. To precipitate the DNA, 8 µl of 4 M NaCl was added, 
followed by the addition of 40 µl of autoclaved 13% PEG 8000 to precipitate the DNA. This 
was mixed thoroughly before the sample was incubated on ice for 20 minutes. The DNA was 
pelleted by centrifugation for 15 minutes at 4°C. The supernatant was carefully decanted and 
the pellet was washed with 500 µl 70% ethanol (as above), before it was dried in a vacuum 
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centrifuge (as above) and resuspended in 20 µl TE-buffer. 
(http://www.biotech.iastate.edu/Facilities/DSSF/plasmid_prep.html). By scaling up the 
amounts of the various buffers and solutions, this proecudre was also used as a midiprep 
procedure. 
Concert Rapid Miniprep 
As an alternate way to prepare small amounts of plasmid DNA, the Concert Rapid Miniprep 
system was used. The manufacturers protocol was followed with one exception: the bacteria 
was occasionally grown in TB-medium in stead of in LB-medium in order to assure a 
sufficient yield of plasmid. 
3.1.20 Large-scale preparations of plasmid DNA (Megaprep) 
In order to attain a high yield of very pure plasmid (which would be needed in experiments 
involving cell cultures) the Qiagen Megaprep kit was used, and the manufacturers protocol 
was followed. 
3.1.21 Determining DNA concentration 
Determining DNA concentration was done by spectrophotometry. The A260 was used to 
measure this, as it is 1 when the DNA concentration is 50 µg/ml for dsDNA and 37 µg/ml for 
single stranded DNA. The purified DNA was diluted in dH2O for measurements by 
specrophotometry, and dH2O was used in the reference cell. The ratio between A260 and A280 
was used to evaluate the purity of the DNA. Optimally this ration should be about 1.8 for pure 
dsDNA. Higher values indicate presence of RNA; lower values indicate the presence of 
proteins or phenol. 
3.1.22 DNA sequencing reaction 
The following reagents were mixed by short vortexing in PCR tubes and spun down in a table 
centrifuge, before thermocycling: 
4 µl Big Dye 
500-1000 ng purified DNA template 
1.6 pmol primer 
dH2O to a total volume of 10 µl in the reaction. 
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The following PCR program was used: 
Initial denaturation step 94° C 5 min 
Cycle:    
Denaturation 96° C 10 sec 
Annealing 50 ° C 5 sec 
Elongation 72° C 4 min  
Repeat cycle 25 times   
Cooling 4° C ∞ 
The samples were delivered directly to the sequencing facility at this point. 
3.2 Computer analyses 
The work with identifying the properties of proteins, their structure, and what molecules they 
can interact with; is facilitated by computer tools and databases. These contain vast amounts 
of sequences of proteins where the functions, the structures and domains with specific 
properties have been identified. These computer tools may elucidate properties of the protein 
you are working with by comparing these sequences to that of your protein. The results 
gained are only theoretical, but may lead towards the final characterization of the protein 
more rapidly. 
Several programs were used to analyse the sequences of Tat101 and Tat115. The predict 
protein tool at the PHD server at Columbia (http://dodo.cpmc.columbia.edu); The PSIPRED 
protein structure prediction server (http://bioinf.cs.ucl.ac.uk/psiform.html), which predicts the 
secondary structure of a protein based on its primary structure; The ScanProsite program 
found at the ExPASy server (http://us.expasy.org/prosite); The ProtParam tool 
(http://us.expasy.org/tools/protparam.html), which calculates theoretical molecular weight, pI, 
and other features of a user provided sequence; PSORT II (http://psort.nibb.ac.jp/form2.html), 
a program that predicts the subcellular localization sites of proteins; Blast and “Blast 2 
sequences” from NCBI (http://www.ncbi.nlm.nih.gov/), which is a sequence alignment tool.  
3.3 Protein purification methods 
3.3.1 SDS polyacrylamide gel electrophoresis 
In order to analyse samples separate proteins were separated by size by SDS polyacrylamide 
gel electrophoresis (SDS-PAGE). The results were visualized by Coomassie blue staining or 
Western blot analysis. The Biorad Mini-PROTEAN 3 Acrylamide gel equipment was used to 
cast and run minigels (8.3 cm width, 7.3 cm height, 0.5 mm thickness). The gels were cast 
with a 4% stacking gel and a 20% separation gel, and 10 wells. The samples were boiled at 
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95° C for 5-15 minutes with after addition of sample buffer to a concentration of 1X. The gels 
were loaded with 10µl sample. The electrophoresis was always carried out at a constant 
current (25-45 mA/gel). 
3.3.2 Coomassie blue staining of gels 
The Coomassie blue colour was routinely used to visualize the proteins on an SDS-PA gel. 
The detection limit of this method is approximately 100 ng. After electrophoresis the gel 
sandwich was opened and the stacking gel cut off. The separation gel was covered with the 
coomassie staining solution and microwaved for 1 minute (until boiling). It was then 
incubated with shaking for 10 minutes, before the staining solution was removed. After 
staining the gel was covered in fix solution, and then microwaved for 1 minute. A piece of 
paper towel was added to the outskirts of the container (so that it did not come in contact with 
the gel) to absorb the dye. The gel was incubated until satisfactory staining was achieved (2-8 
hours). 
3.3.3 Expression of the Tat101 protein 
In this study the Tat proteins were to be expressed in E.coli. The bacteria were transformed 
with a vector, pRSET-C, in which the tat genes were under control of the T7 late promoter. In 
the bacteria used the T7 polymerase gene is regulated by the lac promoter. In the presence of 
lactose or a lactose analogue, such as isopropylthiogalactoside, IPTG, large amounts of T7 
RNA polymerase is produced. Then the polymerase will produce vast amounts of mRNA 
from the tat genes, which will then be used for translation. IPTG was the preferred inducer 
since it cannot be metabolised and the concentration will remain constant through the 
experiment. 
The antibiotics referred to in this procedure are 34 µg/ml CA (chloramphenicol) and 200 
µg/ml amp (ampicillin). 
Electrocompetent E. coli BL21 CodonPlus (DE3)-RIL were transformed by electroporation 
with the plasmid pRSETC-Tat101 and were plated on LB-agar containing antibiotics and 
incubated over night at 37° C. A single colony were inoculated in 5-10 ml LB-medium with 
antibiotics and grown over night at 37° C. 2-3 ml of this culture was the added to 500 ml of 
LB-medium with antibiotics and this was grown at 37° C until the A600 reached 0.5-0.8, and at 
this point IPTG was added to a final concentration of 1 mM, and the culture was incubated 
over night at 30° C (This procedure is modified from Staalesen, 1999). 
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The bacteria were transferred to GSA tubes and harvested by centrifugation at 4000 g for 20 
minutes at 4° C in a sorvall centrifuge, and either the pellet was frozen at -20° C for later use, 
or it was immediately used for purification of the Tat protein.  
3.3.4 Purification of Tat101   
Immobilized Metal ion Affinity Chromatography (IMAC), also known as Metal Chelate 
Affinity Chromatography (MCAC), can be used to quickly and specifically purify a protein or 
peptide. This is a type of adsorption chromatography. The stationary phase consists of a 
binding substance (ligand) immobilized on an insoluble support (matrix). In IMAC the ligand 
is metal ions, for instance Zn2+, Cu2+, Co2+, or Ni2+, which is chelated to the matrix. At a pH 
around neutral these will form complexes with certain amino acids, for example histidine and 
cysteine. It is especially histidine that is responsible for the binding to the chelated metal; 
hence this technique is very effective in the purification of recombinant proteins that have had 
a poly-histidine tag added. The protein can be eluted by reducing the pH, which will alter the 
ionic charge of histidine; by including EDTA in the buffer, which will scavenge the metal 
ions from the matrix; or by adding imidazol to the buffer, which will compete with the protein 
for binding to the metal ions. (Amersham Pharmacia Biotech Handbook). 
Preparation of sample 
The pellet of bacteria in which Tat protein had been expressed was resuspended in 10 ml cold 
Buffer A (section 2.14). To prevent degradation of the protein the following protease 
inhibitors were added: 2 µg/ml aprotinin, 2 µg/ml leupeptin, and 2 mM PMSF. The 
purification of protein was performed immediately after the bacteria had been resuspended. 
This was done to prevent degradation, and the suspension of bacteria was kept at ice during 
the further experiments. The cells were lysed by sonication 3 x 30 seconds with 30 seconds 
intervals while the suspension was kept on ice. The lysate was centrifuged 40 minutes at 
23,000 g at 4° C, to remove cellular debris. The supernatant was then filtrated through a 0.45 
µm sterile filter. 
Affinity Chromatography (FPLC) 
The Tat101 protein was purified in one step by affinity chromatography on an FPLC system 
(Pharmacia). A 1 ml HiTrap Chelating column loaded with Zn2+ ions were used. The flow rate 
was set to 1.0 ml/min and 1-5 ml sample was applied to the column. The column was then 
washed with 10-15 volumes of Buffer A (section 2.14). Ten volumes of Buffer B (section 
2.14) were then used to elute the his-tagged Tat protein from the column. With this buffer 
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change, the collection of 1 ml fractions were started. 110 µl 1 M Tris-Cl pH 8.0 was added to 
each fraction, to raise the pH above 7.0. 
3.3.5 Estimation of protein concentration 
Bradford analysis gave a rough estimate of the amounts of Tat101. The following procedure 
was used: A standard curve was made based on samples of BSA in 0.15 M NaCl in the range 
of 25-100 µg/ml.  100 µl each of the Tat101 solution and the standards were added 1 ml 
Coomassie brilliant blue solution and vortexed.  After exactly 10 minutes at room temperature 
A595 was measured using 100 µl 0.15 M NaCl plus 1 ml Coomassie brilliant blue as blank. 
3.3.6 Storage of Tat protein 
The Tat101 protein was frozen at –20°C or kept at 4°C until it was to be used. 
3.3.7 Western blot analysis. 
Two filter papers were put on each of the pads and were heavily moistened with 1X blotting 
buffer. The SDS-PA gel, on the glass plate, was moistened with blotting buffer and put onto 
one of the filterpapers. A blotting sandwich was then made as folllows: 
From the bottom: The black plate of the blotting plates, a pad, 2 pieces of filter paper, the gel, 
the nitrocellulose membrane, two more pieces of filter paper, a pad and then the whole thing 
was enclosed by the white plate of the blotting plates. While putting together this sandwich, 
bubbles of air between the layers within were removed carefully. The sandwich was put into 
the blotting apparatus, which was then filled with 1X blotting buffer. The blotting apparatus 
was put on ice and the electrophoretic transfer was conducted for 30-45 minutes at 100V. 
After the transfer of proteins, the nitrocellulose membrane was quickly rinsed twice with 
TBS. Then the membrane was incubated in Blocking Solution (section 2.14) for 1 hour at 
room temperature to block the rest of the protein binding sites on the membrane. The 
membrane was then quickly rinsed twice, then once for 15 minutes and twice for five minutes 
with TBS-Tween. The membrane was then incubated with primary antibody at room 
temperature for 1 hour, or over night at 4oC. The primary antibodies were diluted 1:10 (the 
anti-Tat antibodies) or 1:2000 (the anti-polyhistidine antibody). The membrane was rinsed 
twice quickly with TBS-Tween, once for 15 minutes and twice for 5 minutes. Further the 
membrane was incubated for approximately an hour at room temperature with secondary 
antibody (conjugated to Horseradish peroxidase (POD)), which had been diluted 1:2000 in 
 49 
Blocking Solution The membrane was then washed quickly thrice, and once for 15 minutes 
with TBS-Tween, then twice for 5 minutes with TBS. 
The protein bands recognized by the antibodies were visualized with ECL™ Western blotting 
detection reagents from Amersham Life Science by following the producer’s guidelines. 
The membrane was incubated in equal volumes (0.5 ml) of ECL solutions 1 and 2 (in the kit 
from Amersham, section 2.12) (which were mixed by vortexing seconds before their 
application) for 1 to 3 minutes at room temperature. The fluid was allowed to drain off, and 
the membrane was wrapped in plastic. In the dark, light sensitive film was then put upon the 
membrane inside of an X-ray film cassette. Depending on the strength of the signal, the film 
was developed anywhere between 10 seconds and several hours later. 
3.4 Cell culture techniques 
3.4.1 COS-7 Cells 
These are adherent monkey kidney cells. They were grown in IMDM medium with 5-10% 
FCS, and 50 µg/ml Gentamicin. The growth medium was changed 3 times a week. The cells 
were subcloned when 80% confluence was reached. 
3.4.2 Subcloning and harvesting of COS-7 cells 
After a short wash with sterile PBS, 1 ml Trypsin was added to loosen the cells. The trypsin 
was inactivated after 1-2 minutes by adding FCS containing medium. The cells were then 
loosened from the flask wall by aspiration with a sterile pipette. The cell-containing medium, 
or parts of it, was discarded or transferred to another cell flask for expansion. For harvesting 
the cells were collected by centrifugation at 190 g for 2 minutes and the medium was 
discarded. 
3.4.3 Transfection by electroporation 
Cells were trypsinated and harvested by centrifugation at 190 g for 2 minutes. They were then 
washed in 10 ml sucrose buffer. The cells were harvested again, and resuspended in 1-2 ml 
sucrose buffer. For each electroporation 2.5-5 µg plasmid was added to 150 µl of the cell 
suspension and transferred to an electroporation cuvette. The mix was put on ice for 5 minutes 
before electroporation. The settings on the electroporator (Bio-Rad Gene Pulser II with an RF 
module) are shown on the next page:  
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Voltage 200 
% Mod 100 
DC Ampl 100 
RF (kHz) 40 
Burst Dur (msec) 2 
No burst 5 
Burst interv. 1 
3.4.4 Transfection by CaSO4 precipitation  
The cells to be transfected were grown in either a 6-well plate or 24-well plate, to a density of 
50-75%.  The plasmid with which the cells were to be transfected was diluted with dH2O to a 
total volume of 439 µl. 61 µl of 2M CaCl2 were added, and the solution was vortexed. 500 µl 
of 2X HBS (section 2.14) was added, the solution was vortexed, and incubated at room 
temperature for 10-30 minutes. The mixture was added drop by drop to the medium above the 
cells (250 µl per well in a 24 well plate and 1 ml per well in a 6 well plate). The cells were 
incubated with the mixture for 18-24 hours. The medium was removed, and the cells washed 
1–2 times with PBS before fresh medium was added to the cells. The cells were examined the 
next day. 
3.4.5 A biological assay for Tat function 
The HIV-1 LTR promoter is heavily dependent on Tat to produce functional mRNAs. This 
makes it possible to study the transcriptional activity of Tat. An LTR-reporter gene construct 
is transfected transiently or permanently into a cell culture and the activity of Tat can be 
measured by measuring the increased amounts or increased activity of the reporter protein. 
The reporter gene may for instance be EGFP, β-Galactosidase or Chloramphenicol Acetyl 
Transferase (CAT). In this study the LTR-CAT plasmid was used. Tat can then be expressed 
from a plasmid that has been co-transfected into these cells. Alternately this assay can be used 
to measure the uptake of extracellular Tat. This can be done by adding purified protein into 
the media in which these cells grow, or by transfecting other cells with the plasmid containing 
the tat gene and co-culture these cells with the cells containing the reporter plasmid. In the 
latter case one can detect a transcellular activity of Tat. 
3.4.6 Preparation of cell lysates for Western blot analysis 
The cells were lysed after having been incubated at 37° C for 48 hours. The cells were washed 
twice with cold PBS on ice. To each well 150 µl hypotonic buffer was added. The cells were 
collected with a cell scraper and transferred to an eppendorf tube containing 50 µl 4X sample 
buffer. The samples were then run on SDS-PAGE, or stored at –20° C for later use (Szilvay et 
al., 1995). 
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3.4.7 Detecting cellular localization by fluorescence microscopy 
To determine the intracellular location of a protein, it can be labelled with a fluorescing agent 
and viewed by fluorescence microscopy. This can be done by immunofluorescence 
techniques, where antibodies specifically binding to an antigen have been conjugated with a 
fluorescing molecule; or by expressing the protein of interest from a vector, where the gene 
for the protein to be viewed is fused with the gene for a fluorescing protein, such that a fusion 
protein is generated. Green Fluorescent Protein (GFP), Red Fluorescent Protein (RFP), Blue 
Fluorescent Protein (BFP), Cyan Fluorescent Protein (CFP), and Yellow Fluorescent Protein 
(YFP) are all available fusion partners in commercial vectors. In this study the tat genes were 
fused to EGFP in the pEGFP-C1 vector. 
Fig 3.4. The principle of
fluorescence microscopy. A
chromatic filter makes sure
that light of only one
wavelength reaches the
sample. If this wavelength
corresponds to the
excitation maximum of a
chromophore (which in this
figure is EGFP), then the
chromophore will emit light
of a different wavelength.
The light will then pass
through a second chromatic
filter that makes sure only
light emitted by the
chromophore is visible. 
 
3.4.8 Indirect immunofluorescence analysis 
In order to visualize specific proteins in the cells, the coverslips on which the COS-7 cells 
were growing were washed twice with approximately 1 ml PBS in the wells, before they were 
incubated for 20 minutes at room temperature in 0.5 ml cold 4% paraformaldehyde (PFA) in 
PBS. The cells were subsequently washed once in PBS, and incubated for a minimum of 20 
minutes at –20°C covered in pre-chilled methanol. The methanol was removed and the cells 
were washed three times with PBS.  
Following this the coverslips were removed from their wells and placed, cells down, onto 
drops (30 µl) of a blocking buffer, 0.5% BSA in PBS, and were incubated for 15 minutes. The 
coverslips were then moved onto drops (25 µl) of primary antibody (the dilutions would vary, 
1:10, 1:50, 1:400 depending on the antibody) and incubated for an hour at room temperature. 
The coverslips were washed thrice for 10 minutes on drops of PBS, and incubated 1 hour in 
the dark on 25µl drops of secondary antibody conjugated with Alexa568 (diluted 1:100, 1:200, 
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or 1:600) at room temperature. When cells were to be examined only by the fluorescence of 
EGFP, then the steps in this paragraph were not performed. 
The coverslips were washed thrice for 10 minutes on drops of PBS before washed briefly in 
dH2O and mounted onto an object glass in 5 µl Slow-Fade mounting medium (Molecular 
Probes Inc.).  The coverslips were then examined by fluorescence microscopy. 
3.4.9 Microscopy and images 
The immunostained and EGFP containing cells were visualised by using microscopes with 
filters for Alexa568 and EGFP. The images were directly captured and stored digitally by using 
Open Lab imaging (Leica Microscope linked to a MacIntosh computer). The figures were 
created using Adobe Photoshop 7.0. 
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4 Results 
The Tat protein of HIV-1 was to be studied. Of particular interest was its second exon. A 
truncated 86 amino acid version of the Tat protein with the sequence from the HXB3 clone 
had already been extensively studied. It was decided to construct a full-length 101 amino acid 
long Tat variant based on the sequence of this clone. A point mutation at codon 87 would 
replace the premature stop codon, and this would render a gene encoding 101 amino acid 
residues. Any differences in the protein’s abilities could then only be ascribed to whether the 
protein had a complete exon 2. This 101 amino acid variant was named Tat101. Another 
variant of the Tat protein was also to be studied in order to possibly gain new insights from 
the comparison of the two variants. It was decided to use the MVP5180 sequence as a basis 
for the other Tat protein to be studied. The gene to be constructed is called tat115, since it 
encodes a 115 amino acid protein. The sequence used in the following computer analyses is 
based on the tat115 gene that was created, and not on the tat gene from MVP5180. One 
nucleotide differs between the tat115 gene and the tat gene from MVP5180. This difference 
leads to an amino acid change, from serine at position 97 to threonine. 
4.1 Computer analyses of the different Tat proteins 
Different bioinformatical approaches were taken to analyze the amino acid sequences of 
Tat101 and Tat115. Results obtained from the Blast program, PSIPRED, PSORT II, and 
ScanProsite were assembled and compared (figure 4.1). The data that were used in the 
creation of this figure are included in the appendix (sections A.2.3 to A.2.8). 
The Blast program aligned the two proteins so that maximum homology was obtained. This 
alignment made the comparison between the protein sequences easier. It resulted in a gap of 6 
amino acids in the Tat115 sequence and a gap of 5 amino acids in the Tat101 sequence. This 
is shown in figure 4.1 A. In figure 4.1 B the regions that were not included by the Blast 
program have been manually added. The aligned sequence in this figure has been expanded 
with the appropriate amino acids. The homology investigation showed that the proteins have a 
high degree of similarity for the first 54 amino acids, 37 of these being identical, and 8 of the 
remaining 17 amino acids in this region have similar chemical properties. In the remainder of 
the proteins there is very little similarity, except for a stretch of ten amino acids, 86-95 of 
Tat101 and 85-94 of Tat115. Seven of these ten amino acids are identical, while 2 of the 
others have similar chemical properties. The apparent conservation indicates that this domain
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has a biological function. This novel domain was named the EK domain to reflect its high 
content of glutamate and lysine. 
In figure 4.1 B the results from the ScanProsite tool as well as the PSORT II tool have been 
marked in colour. They show that both proteins have a cystein rich domain comprising amino 
acid residues 22-37, and a nuclear localization signal, NLS. In Tat101 this NLS was predicted 
to consist of amino acids 49-53, while in Tat115 it was predicted to be amino acids 49-54. 
The Tat101 protein has previously been reported to have an NLS consisting of amino acids 
49-57 that also functions as a Nucleolar localization signal, NOS (Jeang et al., 1999). The 
PSORT II program also indicated a novel second NLS, PKESKKK, in the Tat101 protein, at 
amino acids 84-90. This sequence is not found in Tat115, even though it is partially located in 
the EK domain, where there is homology between the two proteins. The PSORT II program 
also indicated that the NLS in Tat115 at residues 49-54 may be a part of a bipartite NLS that 
includes the lysines 40 and 41. Furthermore, this program predicted that some threonines and 
serines may be phosphorylated in these proteins. Phosphorylation of these could be a 
mechanism for modulating the functions of the Tat protein. However, the amino acids that 
were predicted to be phosphorylated are not located at the same positions in the two different 
proteins. 
Figure 4.1.C gives an overview of the different domains of the proteins. The different 
domains have been marked in different colours. The naming and location of the domains are 
based on earlier studies of Tat protein from HIV-1 group M, like Tat101. There is a high 
degree of homology between the first 54 amino acids of the two Tat proteins. The proline 
rich, the cystein rich, the core and the RNA binding domain; have been marked similarly in 
the two proteins. The RNA binding domain of Tat101 is shown to stretch three residues 
further than that of Tat115 in order to include three arginines. Then a glutamine rich domain 
is shown in purple. No such glutamine rich domain was found in Tat115, and the remainder of 
that protein is shown in grey to indicate the lack of any known domain. The exception is the 
EK domain mentioned previously. This domain has been marked in orange. 
PSIPRED was used to predict the secondary structure of the two proteins. The results are 
shown in figure 4.1.D, and they were aligned in accordance with the Blast result in 4.1.A. 
Large parts of these two proteins do not seem to have a secondary structure. Amino acids 28-
40 were predicted to be helical in both proteins, and amino acids 44-46 of Tat115 and 44-45 
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of Tat101 were predicted to be β-strands. Furthermore, the program predicted that there is 
secondary structure in the EK domain: helical in Tat101 and β-strand structure in Tat115. 
4.2 Construction of genes, cloning of genes into vectors 
4.2.1 The construction of the tat101 and tat115 genes 
The tat101 gene was constructed by amplifying the tat86 gene from the vector EGFP-Tat86 
with Primers A and B, and by constructing the remainder of the tat101 gene with Primers C 
and D (Materials, section 2.8). These two sequences were designed to be overlapping and 
were amplified with Primers A and D, as described in Methods, section 3.1.3. The sequence 
for the tat86 gene, as found in the EGFP-Tat86 vector, comes from the HXB3 isolate and 
encodes the first 86 codons of the resulting tat101 gene.  
The tat115 gene was created by using 6 large oligonucleotides called Tatmvp1-6, and was 
amplified by using two smaller ones, Tatmvpa and Tamvpb (Materials, section 2.8), as 
described in Methods, section 3.1.4.  
 
Agarose gels (section 3.1.5) were run to confirm that the PCR
and were also used as a means to estimate the yield of the PCR
product containing the tat101 gene was expected to be about
no visible middle product in the two first PCR reactions that
 Figure 4.2: Agarose gel analysis of
the PCR reactions resulting in the
construction of tat101 and tat115. The
pGEM size markers were used, and
the relative sizes are inidcated at the
side of the gels. A) In the first
reaction the tat86 gene is amplified,
but only the EGFP-Tat86 plasmid and
the primers used can be seen on the
gel. In the second PCR reaction the
primers primer C and D have been
run to create the end fragment of
tat101. Only the primers can be seen
on the gel. B) In the third PCR
reaction, 1 µl of each of the two
former PCR reactions have been used
as template, and the agarose gel
analysis shows that the product of this
reaction is as expected a little over
300 bp. In C the PCR reactions
resulting in the construction of tat115.
The first reaction yields a smear on
the gel. In the second reaction this
smear is used as template, and the size
of the PCR-result in this reaction was
as expected approximately 370 bp.   products were of expected size, 
 reaction (figure 4.2). The PCR 
 320 bp. In figure 4.2.A there is 
 were to generate tat101. But in 
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the third PCR reaction (figure 4.2.B) where the products of these reactions are used as 
template, the expected band of ~320 bp is visible. The PCR product containing the tat115 
gene was expected to be about 370 bp. In figure 4.2.C it can be seen that the first PCR 
reaction that was to generate tat115 generated a smear, and that in the second PCR reaction, 
in which the product of the first was used as a template, the expected tat115 band of ~370 bp 
appears. 
4.2.2 The construction of the EGFP-Tat101 and EGFP-Tat115 plasmids 
The EGFP-Tat101 and EGFP-Tat115 plasmids were constructed as outlined in section 3.1.5. 
The tat genes were ligated into the pEGFP-C1 plasmid such that the gene product would be 
fused with the EGFP protein. This allowed for the determination of the intracellular 
distribution of the Tat proteins. 
The purified plasmid from these was then investigated 
by restriction enzyme analysis. The assumed EGFP-
Tat115 plasmid was cut with BamHI and HindIII, while 
the assumed EGFP-Tat101 plasmid was cut with EcoRI 
and HindIII. The restriction enzyme analysis of the 
possible EGFP-Tat115 plasmids is shown in figure 4.3. 
A band of the expected size, ~370 bp, excised from 
several of the plasmids was observed (figure 4.3, lanes 
1-3 and 5). The corresponding data for EGFP-Tat101 is 
not shown.  
The plasmids were then sequenced, and purified in 
larger amounts. The identities of these purified 
plasmids were established by restriction enzyme 
analysis (fig 4.4). In figure 4.4.A and Bit can be seen 
that a band of correct size, ~300 bp for tat101 and 
~370 bp for tat115, is excised from the purified EGFP-
Tat plasmids when they are digested with the Figure 4.3: Restriction enzyme analysis of
EGFP-Tat115 plasmid preps. 1-5 are different
minipreps digested with BamHI and HindIII. If
they contained the tat115 gene, a band of
approximately 370 bp in addition to the plasmid
band of approximately 4700 bp would be seen.
As seen in the figure, 1-3 and 5 show this, while
4 does not, and that indicates that it is in all
likelihood the religated EGFP-C1 plasmid. The
pGEM Markers and λ/HindIII digest have been
used as size markers. The relative sizes are
indicated at each side of the gel. restriction enzymes that were used to ligate the tat genes into the pEGFP-C1 plasmid.  An 
outline of the resultant plasmids is shown in figure 4.11. These constructed vectors were used 
in the experiments in sections 4.4.1 and 4.4.2. 
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 Figure 4.4: Restriction enzyme
analyses of the EGFP-Tat101 and the
EGFP-Tat115 plasmids. The pGEM
Markers and λ/HindIII digest have
been used as size markers. The
relative sizes are indicated at each
side of the gels. A) Analysis of the
EGFP-Tat101 plasmid after
purification by megaprep.  When
digested with BamHI and EcoRI, the
two restriction enzymes used prior to
ligation, a fragment of ~300 bp, the
expected size of tat101, was visible.
This is also shown by comparison to
the band cut out of the EGFP-
Tat86plasmid with the enzymes MluI
and BamHI, which is supposed to
yield a band of that size. B) Analysis
of the EGFP-Tat115 plasmid after
purification by megaprep.  The
expected size of tat115 is ~370 bp,
and when this plasmid is digested
with BamHI and HindIII, the two
restriction enzymes used prior to
ligation, a fragment of that size is
visible. 
4.2.3 The construction of the pRSET-Tat101 plasmid 
The tat genes were inserted into the pRSET-C vector. When 
the pRSET-Tat101 vector was constructed, this was done as 
outlined in section 3.1.6.  
The tat101 and tat115 were amplified by PCR. Figure 4.5 
shows that the PCR products were of the expected size (~300 
and ~370 bp). The PCR product containing the tat101 gene 
was ligated into the pRSET-C plasmid. The purified plasmid 
from this reaction was subjected to restriction enzyme analysis 
(figure 4.6). This figure shows that a band of the correct size 
was excised from two of the three plasmids analysed on that 
gel, when these plasmids were digested with both of the two 
restriction enzymes used when the tat101 gene was ligated 
into the plasmid, but not when only one of these was used. 
These plasmids were then sequenced to establish their 
identity, and one of them were purified in large amounts. As a 
Figure 4.5: Agarose gel analysis of
PCR products. The gel shows the
PCR reactions where tat101 and
tat115 have been amplified. The size
of the PCR-results were as expected,
approximately 300 and 370 bp, and
no  other products can be seen. The
pGEM Markers and λ/HindIII digest
have been used as size markers. The
relative sizes are indicated at each
side of the gel. 
 59 
final insurance that it was the correct plasmid that had been obtained, the identity of this 
plasmid was afterwards verified by restriction enzyme analysis (figure 4.7), which showed the 
plasmid to have the correct pattern like two of the plasmids in figure 4.6.  This plasmid was 
further used in the experiments in section 4.3.1. 
       
Figure 4.7: Restriction enzyme analysis of the pRSET-
Tat101 plasmid after purification by megaprep.  When
digested with EcoRI and XhoI, the two restriction enzymes
used prior to ligation, a fragment of ~300 bp, the same as
tat101, was visible in addition to the main plasmid band of
ca. 2700 bp. The pGEM Markers and λ/HindIII digest have
been used as size markers. The relative sizes are indicated to
each side of the gel. 
 
 Figure 4.6: Restriction enzyme analysis of the pRSET-
Tat101 plasmid. 1-3 are different minipreps of bacteria
transformed with pRSET-C ligated with the tat101
gene. In A they have been digested with XhoI and
EcoRI, in B EcoRI, in C XhoI, and in D they have not
been digested with any restriction enzymes. XhoI and
EcoRI were the enzymes used prior to ligation and one
would expect a band of approximately 300 bp to have
been cut out of the pRSET plasmid with those two
enzymes if the gene had been ligated into the vector.
This can be seen for 1 and 2, but not 3. The pGEM
Markers has been used as a size marker. The relative
sizes are indicated to the right of the gel. 4.2.4 The construction of the pRSET-Tat115 plasmid 
The pRSET-Tat115 plasmid was constructed as outlined in section 3.1.7. The PCR product 
containing the tat115 gene was subcloned into a TOPO vector, pCR-BLUNT II-TOPO. This 
was followed by restriction enzyme analysis. The results (figure 4.8) showed that only one 
clone contained the tat115 gen. The tat115 gene was then ligated into the pRSET-C vector, in 
a similar manner as done with the tat101 gene (section 4.2.3). Figure 4.9 shows the restriction 
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enzyme analysis of the plasmid preps. This figure shows that the tat115 gene had been cloned 
into two of three clones. Figure 4.10 shows an agarose gel analysis of the purified pRSET-
Tat115 plasmid. DNA sequencing affirmed the identity of the plasmid. Figure 4.11 outlines 
the most important features of the different Tat plasmids created. These plasmids were used in 
the experiments described in sections 4.3.1, 4.4.1 and 4.4.2. 
    
Figure 4.8: Restriction enzyme analysis of the pCR-
BLUNT II-TOPO vector after the tat115 gene had been
subcloned into it. Lanes 1-12 contain different
minipreps. All the minipreps have been digested with
XhoI, which should lead to the release of a fragment of
approximately 450 bp. This can be seen in lane 5. The
pGEM Markers has been used as a size marker. The
relative sizes are indicated at the right of the gel. 
 
 
Figure 4.9: Restriction enzyme analysis of the pRSET-
Tat115 plasmid. 1-3 are different minipreps. In A they
have been digested with BamHI (there is a cleavage site
for this enzyme within the tat115 gene, and if the plasmid
is linearised by treatmeant with this enzyme, this would
show that the correct gene has been inserted. In B EcoRI,
in C EcoRI and XhoI, and in D XhoI. The restriction
enzymes used prior to ligation were EcoRI and XhoI, and
a fragment of approximately 350 bp when the plasmid
had been digested with both these enzymes would show
the correct insert. This can be seen for minipreps 1 and 2.
3 seems to be a failed miniprep. The pGEM Markers has
been used as a size marker. The relative sizes are
indicated at the right of the gel. 
 
Figure 4.10: Agarose gel
analysis of thepRSET-Tat115
plasmid. After the miniprep,
pRSET-Tat115 was purified
by midiprep. A plasmid of the
same size as that in the
miniprep was purified, and
identity was established by
DNA sequencing of the
miniprep. The pGEM Markers
and λ/HindIII digest have
been used as size markers. The
relative sizes are indicated at
each side of the gel. 
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Figure 4.11: The resultant plasmids to be used in the further experiments (sections 4.3.1, 4.4.1 and 4.4.2). EGFP-Tat72 and 
EGFP-Tat86 were kindly provided by Vibeke Andresen and have the same basic elements as the EGFP-Tat115 and EGFP-
Tat101 plasmids constructed in this thesis. 
4.3 Purification of Tat protein 
4.3.1 Expression and affinity chromatography of Tat101 
The Tat101 protein was expressed recombinantly using the pRSET-Tat101 vector (3.3.3), and 
was successfully purified by affinity chromatography (3.3.4). The supernatant of bacterial 
lysate from the bacteria transformed with pRSET-Tat101 was run through the Hitrap 
chelating column on the FPLC system. The chromatogram showed a large peak after the 
sample has been applied to the column, which indicated that most of the proteins in the lysate 
were washed out with the flowthrough. After the pH was changed to 4.0, a small peak 
emerged, indicating that the Tat101 protein was indeed expressed, and was purified (figure 
4.12). When bacteria transformed with the empty pRSET-C vector, there was no such peak 
released at pH 4.0 (data not shown). This indicates that it was indeed the 6Xhis-Tat101 
protein that had been purified. The same procedure was attempted to purify the Tat115 
protein. However, the amount of purified Tat115 protein was too small to be used in the 
transcellular activity assay. In figure 4.13 samples from the different stages of purification of 
the Tat101 protein have been run on SDS-PAGE (section 3.3.1). In A the proteins have been 
visualized by Coomassie blue colour (section 3.3.2), and in B the Tat protein is detected by 
Western blot (section 3.3.7). 
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FPLC chromatogram of the purification of Tat101
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Figure 4.12:  A chromatogram showing the purification of the Tat101 protein. The left axis shows the scale of the A280 
values, which are shown drawn in blue. The right axis shows the percentage of Buffer B used, which is drawn in pink. At 0% 
B, the pH is 8.0, at 100% B, the pH is 4.0. Most of the filtrated bacterial lysate was flushed through with Buffer A (pH 8.0). 
The buffer was changed to Buffer B (pH 4.0). Anything that had bound to the Zn2+ on the column was then released. It can be 
seen that a small top does emerge in the A280 after addition of Buffer B.  
 
A 
 
B 
Figure 4.13: Two similar SDS-PAGE were run to document the purification of the Tat101 protein. In A the proteins on the 
gel have been visualised by Coomassie blue staining, while in B the contents of the gel have been subject to Western blot 
analysis using the mAb 1D9D5 as primary antibody, and anti-mouse conjugated to POD as secondary antibody. The Western 
blot was developed by ECL. In B lanes 1-4 had been diluted 1:450 when compared to the amounts applied to the gel shown 
in A. The NEB prestained broad range standard was used as a size marker, and the relative sizes are indicated to the left. 
What was applied in the different lanes: Lane 1: Total protein from E.coli transfected with pRSET-C, Lane 2: Total protein 
from E.coli transfected with the pRSET-Tat101 plasmid, Lane 3: Pellet after sonication of E.coli transfected with the pRSET-
Tat101 plasmid, Lane 4: Supernatant after sonication of E.coli transfected with the pRSET-Tat101 plasmid, Lane 5: Fraction 
7 eluted after the filtrated supernatant after sonication of E.coli transfected with the pRSET-Tat101 plasmid on a HiTrap 
chelating FPLC column, Lane 6: Fraction 8 eluted after the filtrated supernatant after sonication of E.coli transfected with the 
pRSET-Tat101 plasmid on a HiTrap chelating FPLC column, Lane 7: Previously purified 6Xhis Tat86 protein (Mendonca 
and Lavoura, 1998) 
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In A, none of the lanes 2, 3 and 4, where the samples come from bacteria transformed with the 
pRSET-Tat101 plasmid, differ significantly from lane 1, where the sample comes from 
bacteria transformed with the empty pRSET-C vector. But the fractions taken when the top 
emerged in figure 4.12 contained a few clear bands. One of these is slightly smaller than 17 
kD, as seen in lanes 5 and 6, showing that something had indeed been purified. When the 
sizes of these bands were compared with those in lane 7, where previously purified Tat86 
protein had been run, the bands were of expected and comparable size, indicating that it was 
Tat protein that had been purified. On the Western blot (figure 4.13.B) there are two bands in 
all the lanes where the samples originated from bacteria transformed with pRSET-Tat101, 
except from lane 6 where only one is visible and barely so, while no such bands are visible 
when the bacteria had been transformed with pRSET-C. This showed that the Tat101 protein 
had been expressed and purified, and also suggested that in addition to the full fusion protein, 
a smaller, possibly degraded version of the protein was purified along with it. If this was 
indeed a degraded version of the protein, then this was a good opportunity to test the epitope 
specificity of some monoclonal anti-Tat antibodies previously shown to bind to a peptide 
spanning amino acids 49-86 (Valvatne et al., 1996). This was done in section 4.3.2, and the 
purified protein was further used in section 4.4.1. 
4.3.2 Attempted epitope mapping of anti-Tat antibodies 
A Western blot was run to test the epitope specificity of mAbs 4B4C4, 1D2F11, 2D9E7, and 
5G7D8 (section 3.3.7). Each lane contained extract from bacteria induced to express the 
Tat101 protein. The Western blot was cut into strips and each of the antibodies to be tested 
was incubated with one of the strips. An antibody shown to bind to a peptide spanning amino 
acids 1-20 of Tat, 1D9D5, was used as a control, as was an antibody binding to the his-tag of 
the fusion protein. As can be seen in figure 4.14, several bands turned up when the Western 
blot was developed. Since lane 1 in figure 4.13.B showed that no bacterial proteins reacted 
with the primary antibody 1D9D5 and the secondary anti-mouse antibody, the more powerful 
bands in the Western blot in figure 4.14 were thought to be Tat protein. The anticipated Tat 
band at approximately 16.5 kD is there, and any bands larger than this are possibly multimeric 
forms of Tat. All the lanes showed a band that was a little smaller than 16.5 kD. Seeing how 
this band also was present in the lane where the anti-his antibody had been used, the 
degradation of the protein could not have been N-terminal.  
In some, but not all the lanes a third band, a little smaller than these first two was present. The 
first lane, where the anti-his antibody had been used, does not show the band in this figure, 
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but when the Western blot was overexposed (data not shown) this band was discernible also 
in this lane, showing that the putative degradation of the protein could only to a small extent 
have been N-terminal, and that most, if not all, of the amino acids missing (which would 
explain the small size of the band), were from the C-terminus. The lanes where the antibodies 
1D9D5, 4B4C4 and 1D2F11 were used, show this band clearly, while the lane where 5G7D8 
has been used shows this band a little bit less clearly. However, the lane where the antibody 
2D9E7 has been used does not show this band. This would indicate that 2D9E7 binds to an 
epitope closer to the C-terminus of the Tat protein than the others. The fact that this band 
turns up in some but not all of the lanes excludes the possibility that the band is caused by the 
secondary antibody binding to a bacterial protein, and the fact that primary antibodies shown 
to bind different epitopes indicate the same band show that the protein is probably a modified 
version of Tat.  
 
Figure 4.14: This Western blot was performed to see if the epitopes to which the different antibodies bind could be more 
clearly defined. In each well there was applied the supernatant after sonication of E.coli transfected with the pRSET-Tat101 
plasmid, as seen in lane 4 of figure 4.14.B. The negative control in lane 1 of that same figure was thought appropriate for use 
in this figure as well. In lanes 1-6 monoclonal antibodies recognizing different epitopes on the 6xhis-Tat101 protein have 
been used. The Broad Range Standard (NEB) is used to show the size of the bands, and the relative sizes are indicated to the 
left. The primary antibody used in the different lanes: Lane 1: Anti-his-tag antibody, lane 2: 1D9D5, lane 3: 4B4C4, lane 4: 
1D2F11, lane 5: 2D9E7, lane 6: 5G7D8. The secondary antibody was anti-mouse conjugated to POD, and the Western blot 
was developed by ECL. 
Calculations were made to determine the sizes of the proteins seen in these bands in kD and 
the number of amino acids, to be able to define the location of the epitopes these antibodies 
bind to (data not shown). From smallest to largest, the three bands recognized as 6xhis-Tat 
were 16.5, 10 and 8 kD, corresponding to Tat proteins consisting of 96, 55 and 28 amino acids 
when the N-terminal 39 amino acids of the fusion partner has been subtracted. This would 
then indicate that all the mAbs to be tested but 2D9E7 bind an epitope between amino acid 1-
28, while 2D9E7 bind an epitope between 1 and 55. 
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4.4 Studies of Tat function and cellular localization studies of Tat  
4.4.1 Expression of the CAT protein in COS-7 cells to show 
transcriptional transactivation and transcellular transcriptional 
transactivation 
The transcriptional transactivation activities of the purified Tat protein and the EGFP-Tat 
fusion protein were examined. COS-7 cells transfected with the LTR-CAT construct were 
used in an assay to investigate this (section 3.4.5). Purified Tat protein was added to such cells 
and other cells were co-transfected with the LTR-CAT plasmid and the EGFP-Tat plasmids 
(section 3.4.4). The next day the cells were lysed and CAT expression was detected by 
Western blot (figure 4.15). A band of approximately 25 kD, which is the expected size of 
CAT is visible in lanes 3-8 in that figure. There is no such band in lane 2, where the COS-7 
cells have been transfected with the LTR-CAT vector, but there is no Tat protein present. The 
CAT-band in lane 7, where the sample comes from cells that have had Tat86 protein added to 
the media in which they grow, is very weak, but still discernible. Since the CAT protein was 
detected this shows that the EGFP-Tat115 protein (lane 3), the EGFP-Tat101 protein (lane 4) 
and the 6xhis-Tat101 protein (lane 6) all transactivated the LTR promoter. This Western blot 
also showed that the EGFP-Tat86 protein (lane 5) and purified 6Xhis-Tat86 protein (lane 7) 
transactivates the LTR promoter as expected. Since the CAT protein was expressed when the 
purified Tat101 protein was added to the media (lane 6), this indicated that the protein had 
been taken up by the cells and that it had a transcellular activity. 
T 
Figure 4.15: Western blot analysing the functionality of the Tat101 an
lane contains the NEB prestained protein standard; the sizes of the pro
COS-7 cells transfected with the LTR-CAT vector have been applied. T
with a Tat expressing plasmid, or Tat protein was added to the media. T
2: COS-7 cells transfected with LTR-CAT, lane 3: COS-7 cells transfec
cells transfected with LTR-CAT and EGFP-Tat101, lane 5: COS-7 cells 
COS-7 cells transfected with LTR-CAT and with 7.5 µg 6Xhis Tat101 
COS-7 cells transfected with LTR-CAT and with 7.5 µg 6Xhis Tat86 
COS-7 cells transfected med LTR-CAT and EGFP-Tat101 (from Vibeke
FuGene, while the cells used in the other lanes were transfected by the 
antibody used was the anti-CAT antibody, the secondary antibody used 
blot was developed by ECL. 
 CA 
d Tat115 proteins on the HIV-1 promoter. The first 
teins are indicated to the left. In lanes 2-8 lysate of 
he cells used in lanes 3-8 were either co-transfected 
he cells were lysed 48 hours after transfection. Lane 
ted with LTR-CAT and EGFP-Tat115, lane 4: COS-
transfected with LTR-CAT and EGFP-Tat86, lane 6: 
protein added to the medium after 24 hours, lane 7: 
protein added to the medium after 24 hours, lane 8: 
 Andresen). The cells in lane 8 were transfected with 
calcium sulphate precipitation method. The primary 
was anti-rabbit conjugated to POD, and the Western 
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4.4.2 Intracellular localization of the Tat proteins. 
The main reason for constructing the EGFP-Tat plasmids was to be able to examine the 
cellular distribution of the Tat101 and Tat115 proteins. The plasmids expressing these EGFP 
fusion proteins were transfected into COS-7 cells either by the calcium sulphate precipitation 
method or by electroporation (sections 3.4.3 and 3.4.4). The cells were grown in 24 well 
plates on coverslips and fixed with paraformaldehyde and methanol after approximately 48 
hours in culture (section 3.4.8). The Tat protein was also detected by immunofluorescence 
using the monoclonal antibody 1D9D5, which binds to the N-terminal part of Tat. Tat115 
could however not be detected by immunofluorescence, most likely due to difference in 
sequence in the N-terminal part of Tat. The cells were then examined by fluorescence 
microscopy and images were captured (section 3.4.9). The same experiment was also 
conducted with plasmids expressing EGFP, EGFP-Tat72 and EGFP-Tat86, allowing the 
intracellular distribution of these proteins to be compared with that of EGFP-Tat101 and 
EGFP-Tat115 (figures 4.16 - 4.20).  
 
Figure 4.16: Intracellular localization of EGFP-Tat115 in transfected COS-7 cells. A: The fluorescence of the EGFP moiety 
of EGFP-Tat115, B: The cells visualized by phase contrast image, C: The fluorescence of EGFP overlaid on the phase 
contrast image of the cells. 
 
Figure 4.17: Intracellular localization of EGFP in trasfected COS-7 cells. A: The fluorescence of the EGFP, B: The cells 
visualized by phase contrast image, C: The fluorescence of EGFP overlaid on the phase contrast image of the cells. 
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Figure 4.18: The intracellular localization of EGFP-Tat101 in transfected COS-7 cells. A: The fluorescence of the EGFP 
moiety of EGFP-Tat101, B: Immunofluorescence visualizing Tat in red, C: The cells visualized by phase contrast image, D: 
The immunofluorescence overlaid on the phase contrast image of the cells, E: The fluorescence of EGFP overlaid on the 
phase contrast image of the cells. F: The fluorescence of the EGFP moiety of EGFP-Tat101, G: Immunofluorescence 
visualizing Tat in red, H: The cells visualized by phase contrast image, I: The immunofluorescence overlaid on the phase 
contrast image of the cells, J: The fluorescence of EGFP overlaid on the phase contrast image of the cells. 
 
Figure 4.19: The intracellular localization of EGFP-Tat72 in transfected COS-7 cells. A: The fluorescence of the EGFP 
moiety of EGFP-Tat72, B: Immunofluorescence visualizing Tat in red, C: The cells visualized by phase contrast image, D: 
The immunofluorescence overlaid on the phase contrast image of the cells, E: The fluorescence of EGFP overlaid on the 
phase contrast image of the cells. F: The fluorescence of the EGFP moiety of EGFP-Tat72, G: Immunofluorescence 
visualizing Tat in red, H: The cells visualized by phase contrast image, I: The immunofluorescence overlaid on the phase 
contrast image of the cells, J: The fluorescence of EGFP overlaid on the phase contrast image of the cells. 
 
Figure 4.20: The intracellular localization of EGFP-Tat86 in transfected COS-7 cells. A: The fluorescence of the EGFP 
moiety of EGFP-Tat86, B: Immunofluorescence visualizing Tat in red, C: The cells visualized by phase contrast image, D: 
The immunofluorescence overlaid on the phase contrast image of the cells, E: The fluorescence of EGFP overlaid on the 
phase contrast image of the cells. 
The images showed the location of Tat101, Tat86 and Tat72 by its EGFP moiety (figures 4.18 
(A, E, F, J), 4.19 (A, E, F, J), and 4.20 (A, E)); the proteins were seen mainly in the nucleus 
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and especially the nucleoli. There is a weak fluorescence in the cytoplasm that cannot be 
observed in these images. The results of the immunofluorescence were somewhat 
contradictory when it came to the Tat72 protein and the Tat101 protein as can be seen in the 
figures 4.18 and 4.19. In most cells the results are similar, but with a stronger fluorescence in 
the cytoplasm. However, in some cells the immunofluorescence showed Tat mainly being in 
the cytoplasm, and almost excluded from the nucleus, but in the same cells the pattern is 
different when looking at the fluorescence from the EGFP moiety (figures 4.18.F, 4.18.G, 
4.19.F, and 4.19.G). Since the localization of EGFP is naturally in the nucleus and the 
cytoplasm (figure 4.17), and differs from that of the EGFP-Tat proteins, the intracellular 
localization of the EGFP-Tat proteins is due to properties of the Tat proteins. 
The localization of Tat115 could only be detected through its EGFP moiety, and the images 
show that it differs slightly from that of the others. It was also located mainly in the nucleus 
and the nucleoli and very little in the cytoplasm. But when compared to the other Tat proteins 
in this study it would seem that it is possibly not as concentrated in the nucleoli. 
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5 Discussion 
The Tat protein of HIV-1 has been extensively studied and a plethora of attributes has been 
assigned to it, and to various parts of it. Yet the last part of the second exon encoded region 
has been ignored. This is because the first subtypes of HIV-1 to be studied in detail seem to 
have acquired a point mutation in the 87th codon, inserting a stop there (Jeang et al., 1999). 
However, most wild type variants of the HIV-1 Tat protein have 101 amino acids.  
In this study genes for two variants of the HIV-1 protein Tat were constructed by PCR based 
methods. These genes were called tat101 and tat115. Following construction of these two 
different tat genes, they were inserted into vectors allowing study of the intracellular 
localization of both proteins and purification of the Tat101 protein. When the Tat101 protein 
was purified several subspecies of the protein were detected on Western blot. This was 
thought to indicate that the smaller subspecies had lost C-terminal amino acids. Valvatne et 
al. had previously epitope mapped some monoclonal anti Tat antibodies (1996), and the 
detected Tat subspecies were attempted used to further map the epitopes to which these Anti-
Tat mAbs bind. The trans-activating function of both Tat proteins was verified, and the trans-
cellular activity of the purified Tat101 protein was demonstrated in this work. Computer 
analyses were performed for the two proteins, and a new domain potentially important for the 
function of the protein, as well as a possible novel NLS for Tat101 were identified. 
5.1 Computer based predictions of Tat protein properties 
Bioinformatical analyses of the two different Tat proteins were conducted. Based on these 
analyses a new domain was identified and named the EK domain. Furthermore, a potential 
novel NLS was found for Tat101. Comparison of the two Tat proteins established that several 
domains of Tat101 had their counterparts in Tat115 and that one domain was absent in the 
Tat115 domain, indicating which domains might be essential for Tat function during the HIV 
life cycle.  
Pairwise blast used to align Tat101 with Tat115 showed that amino acids 85-94 of Tat115 and 
86-95 of Tat101 had a strikingly similar motif, E(S,Q)(E,K)EKKVE(R,K)ET. This novel 
domain was named the EK domain to reflect the high content of E and K. Evaluation of the 
sequences of Tat variants present in the Los Alamos catalogue of HIV-1 sequences (section 
A.1.3) indicates that EK is a conserved domain. Motifs similar to the this domain are found in 
several different proteins, including RNA binding proteins (section A.2.10). This domain can 
be part of a larger polar area of the protein. However, all the three reading frames in this part 
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of the HIV-1 genome are used, as part of the tat, rev and env genes. If any one of these 
sequences has an important function, less genetic variation would be found. The nucleotide 
sequence could also be conserved if the RNA sequence forms a secondary structure, or the 
sequence in itself has a function that is important in the HIV life cycle. Examples of this 
would be TAR, exon splicing enhancers, or exon splicing silencers. However, large parts of 
the sequence of the tat gene have not been highly conserved. For instance it has been shown 
that an important RNA element called exon splicing silencer 2 (ESS2) located in the first 
coding exon of the tat gene in strains from HIV-1 group M (these nucleotides encode amino 
acids 6-9 of Tat) is not found in strains from group O (Bilodeau et al., 1999).  
Further investigations to determine whether the corresponding amino acid sequences of Rev 
and Env, and to which extent the nucleotide sequence has been conserved, should be 
performed. If these sequences have been conserved this could indicate that the EK domain 
might just be an artefact with no important function. If these investigations turn out negative, 
it would be prudent to compare the functions of the other proteins that have EK domains. 
Unlike the Tat101 protein, Tat115 has no glutamine rich region. This would indicate that the 
specific amino acid sequence, particularly the high frequency of glutamines, of this region is 
not of critical importance with regards to the HIV life cycle. This assumption is corroborated 
by the fact that no essential functions have yet been designated to this region. 
The RGD sequence found has previously been suggested to confer binding to integrins on the 
cell surface, and it was long thought to be important for the transcellular properties of Tat 
(Valvatne et al., 1996). However, this motif is not highly conserved in Tat (section A.1.3) 
indicating that it is not important for Tat function. 
In Tat 101, the sequence PKESKKK, located at amino acids 84-90, was predicted to be an 
NLS. This sequence is very similar to a motif from the ribosomal L5 protein that confers 
nuclear and nucleolar localization (Rosorius et al., 2000). This sequence is well conserved 
among different sequenced HIV genomes (http://hiv-web.lanl.gov, section A.1.3) indicating 
some biological importance. Why a protein would need to have two NLS is puzzling, if it 
indeed is a NLS. Experiments conducted in order to verify the predicted function of this 
amino acid sequence has not led to conclusive results (Andresen, personal communication). 
The two NLS are located in separate exons; therefore the one-exon variant of Tat (Tat72), 
which is expressed as an HIV late protein, contains only one NLS. That the two-exon variant 
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of Tat is much more rare in the later stages of the HIV life cycle might reflect a need to shut 
off the activities of the second exon, possibly attributes from the NLS and the EK domain. 
Both this potential NLS and the EK domain are absent in the Tat86 protein. These motifs may 
have been detrimental to some HIV strains. Possibly this has caused the mutation that led to 
an 86 amino acid Tat protein, that is encoded by several strains of HIV from group M 
subtypes B and D and H. 
The PSORT II program reports the NLS of Tat115 to possibly be bipartite (Appendix, section 
A.2.5, Results figure 4.1) whether it is, should be an important question to address. 
The predicted phosphorylation sites differ between the two Tat proteins. Péloponèse et al. 
have suggested that differences in phosphorylation might influence the virulence of different 
HIV strains. The electric charge of the phosphate groups could influence interactions with 
other proteins and cellular factors important to its functions. The two proteins might have 
some different functions since the phosphorylation sites have different locations, or they 
accomplish the same functions through different structures.  
Secondary structure computer analysis predicts that Tat101 and Tat115 have similar and 
mostly coiled structure. The two proteins have similar amino acid sequence from 1-54, and 
the regions predicted to have secondary structure up to that are the same. After amino acid 54 
the only secondary structure predicted lies in the EK domain, but in the two Tat variants this 
domain is predicted to have different structures. In Tat115 seven of these amino acids are 
predicted to form a β strand structure, while in Tat101 all ten amino acids are predicted to 
form a helical structure. However, in both proteins the predicted structure has a low 
confidence value for this domain (section A.2.3). The predicted structure does not correlate 
too well with the structure found by Bayer et al. in 1995. Using NMR they found that a Tat86 
from group M subtype D strain did not have any secondary structure at all.  
5.2 Construction of the tat genes 
The tat101 and tat115 genes were constructed through PCR reactions (section 4.2.1). This 
was done in order to study variants of the HIV-1 Tat protein previously not characterized, 
which could lead to new insights relating to the role of Tat in the HIV-1 life cycle. The 
sequence of tat from HXB3 was used as a basis for the sequence of tat101. In the tat101 
sequence the stop codon found at codon 87 of HXB3 has been replaced by a codon for serine, 
which is a common amino acid in that position for other group M subtype B sequences. This 
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strategy required only one nucleotide substitution, indicating that this could be the amino acid 
originally present prior to the mutation that caused the protein to be truncated. The tat115 
gene was constructed based on the sequence from strain MVP5180 of the HIV-1 group O. 
It turned out, however, that the sequence of tat115 had a point mutation compared to the 
original sequence. This was due to an error in the design of the oligonucleotides used to 
construct the gene. The mutation lay in the primer named Tatmvp6 (section 2.8). The 
mutation that occurred in codon 97 was considered to be of less importance as the amino acid 
substitution it caused was from a serine to a threonine, and these two amino acids have similar 
chemical properties. 
5.3 Purification of Tat proteins 
The procedure used to purify the Tat proteins was successful for the Tat101 protein, and this 
protein was used in the further experiments. However, only a very small amount of the Tat115 
protein was purified, and this amount was considered too small to be used in the transcellular 
activity assay. 
The his-tagged protein was released from the column using a buffer with low pH. This change 
of pH might cause a change in the protein structure, denaturing the protein. To minimize any 
degradation of the protein, 1 M Tris-Cl pH 8.0 was added to increase the pH of the samples 
containing the Tat protein immediately following purification. 
There were two clear bands in the Western blots of the purified Tat101 protein (figure 4.13). 
This indicated that despite the several protease inhibitors used in the lysis buffer, some 
degradation of the protein had occurred. It was thought to be due to proteolytic cleavage near 
the C-terminus because the protein would have been washed away with the flowthrough if the 
his-tag located very close to the N terminus had been cut off. That neither of the two bands 
were visible in the lane where bacterial lysate from bacteria transformed with pRSET-C had 
been applied indicated that both of these bands were Tat products.  
One could hypothesize that the low yield of the Tat115 protein was due to problems with the 
codon usage between E.coli and HIV. However, the bacteria used, E. coli BL21 CodonPlus 
(DE3)-RIL, are designed to express proteins with human codon usage. Still, it is possible that 
a different strain of bacteria could have given a higher yield of protein. Another possible 
variation would be differerent growth rates, which can affect the yield of protein. This was not 
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attempted in this work, but several alterations were done in the procedure in unsuccessful 
attempts to express Tat115.  
An explanation for the low yield of Tat115 protein could be the formation of inclusion bodies. 
An attempt to purify more protein by dissolving the bacteria in a buffer containing 8 M urea 
did yield more protein. This suggests that Tat115 was expressed. These samples were not 
studied further. Other variations of the procedure included altering the temperature in which 
the bacteria were incubated, changing the concentration of IPTG and altering the incubation 
time. However, the protein could never be detected against the background in the bacterial 
lysates by Coomassie blue staining of SDS-PAGE. Because of that, these data were not 
included, nor were they followed up. However, as Western blot is a more sensitive way of 
detecting protein, this procedure could perhaps have shown variations that Coomassie blue 
staining of SDS-PAGE could not. In future attempts to purify Tat115, such tests should be 
performed in order to see if variations of procedure to express this protein have any effect. 
5.4 Attempted epitope mapping of antibodies 
In the Western blot in figure 4.13 it can be seen that there are two bands in the lanes where the 
Tat protein has been purified. Neither of these two bands is present in the lane where lysate of 
the bacteria transformed with the empty pRSET-C vector have been applied. This means that 
both bands occured as a result of the expression of Tat in the bacteria, and that they likely are 
both the Tat protein, and not the result of either antibody (1D9D5 and the anti-mouse 
antibody) binding to a bacterial protein. This must mean that a fraction of the Tat protein in 
some way had been modified so that it migrated faster through the gel. This could be 
explained by the net charge of the protein having become more negative through chemical 
modifications, or that the physical size of the protein had been decreased, either by loss of 
amino acid residues through proteolytic cleavage, or through different folding of the protein.  
 The two subspecies of Tat on the Western blot (figure 4.13) were assumed to be caused by 
one of them having been proteolytically cleaved near the C-terminus. This phenomenon was 
then used to investigate some mAbs for Tat that had been mapped to the area 49-86 (Valvatne 
et al., 1996). The antibodies are thought to be dependent on the folded conformation of the 
protein to be able to bind. On the Western blot (figure 4.14) two clear bands were visible in 
each lane, regardless of which anti-Tat antibody was used. However, a third band was visible 
in all lanes but one. That the same band was visible in lanes where antibodies binding to 
different epitopes were used, excluded the possibility of this band being the result of the 
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antibodies binding to a bacterial protein found in the lysate. This indicated that this third band 
either was a third Tat subspecies present, one in which more of the protein had been cleaved 
off, or that this band was a result of unspecific binding by the secondary antibody. That it was 
not present in all lanes excluded the possibility of the latter. The presence of this band in the 
1D9D5 lane, as well as in the anti-his lane when overexposed, indicated that the amino acids 
lost were C-terminal. Since this band was not seen in the lane where the antibody 2D9E7 had 
been applied this indicated that this mAb binds to an epitope closer to the C terminus than the 
others.  
However, when the sizes of these bands were estimated, the uppermost of the three bands 
showed approximately the estimated size of the 6Xhis-Tat101 protein, while the two smaller 
bands seemed to be too small to contain the epitope to which the mAbs bind. Valvatne et al. 
showed these mAbs to bind a peptide encompassing amino acids 49-86 of Tat, and 
hypothesized that the entire peptide was needed for the correct folding of the epitope they 
bind to. This was because the mAbs did not bind to overlapping 20-mer peptides covering this 
region, and did not bind to a full-length inactive recombinant Tat protein. Since these bands 
seem too small to contain the epitope, the hypothesis that the bands on the Western blot are 
due to proteolytic cleavage of the 6Xhis-Tat101 protein does not agree with the results of 
Valvatne et al. (1996). Then it becomes more likely that the faster migration through the gel 
of these bands is due to chemical modification of the Tat protein seen in these bands, giving 
them a more negative charge. This could be due to deamidation of glutamines and 
asparagines, by being exposed to high temperature during the boiling of the samples in the 
SDS-PAGE procedure, or there could be differences in the charge of the protein species due 
to covalently attached non-protein moieties, like phosphate.  
5.5 Cellular uptake of Tat and transactivation  
By detecting the expression of the reporter protein CAT on Western blot, it was shown that 
the EGFP-Tat fusion proteins transactivate the LTR promoter. This means that the EGFP 
moiety of the fusion proteins does not have an effect on the conformation of Tat in any 
manner that would affect its transactivating activity.  
The LTR used was from HXB3. Tat115 is from the MVP5180 strain, from HIV-1 group O, 
and is a somewhat distant relative. As the tat gene evolved in MVP5180 as did the TAR 
element. Any mutations in either Tat or TAR that decreases binding affinity between them 
would be responded with a mutation in the other adjusting it, for the virus to compete in its 
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host. Tat protein from HIV-1 subtype B has been shown to have different transactivating 
properties on LTRs from different subtypes within group M (Montano et al., 1997; Jeeninga 
et al., 2000). One would expect from this that the Tat115 protein might not efficiently 
transactivate this promoter, however it did, and seemingly slightly more efficiently than the 
EGFP-Tat86 protein.  
The purified 6Xhis-Tat101 protein was also shown to transactivate the LTR promoter in these 
cells when added to the media, demonstrating that it was taken up by the cells. The fact that 
there was a CAT band in the lane with cells where his-tagged Tat protein had been added, 
shows that this protein was internalised into the cells and that it managed to transactivate the 
promoter. This indicates that the additional 15 amino acids, 87-101, have no clear detrimental 
effect on the cellular uptake of Tat.  
As a positive control cells co-transfected by the EGFP-Tat101 plasmid and the LTR-CAT 
plasmid were used. Lane 8 in figure 4.15 shows a much stronger CAT band. It should be 
noted that Vibeke Andresen provided this sample and that the more efficient FuGene 
procedure had been used for transfection. In the lane showing the lysates of cells transfected 
with the LTR-CAT plasmid alone there is no clear band around 25 kD, one such can be seen 
very clearly in the positive control. The his-tagged Tat86 protein was used as a positive 
control, but does not seem to have been functional, indicating that something could have been 
wrong with the sample.  
5.6 Intracellular localization of the different Tat variants 
By fluorescence microscopy the EGFP-Tat101 and EGFP-Tat115 proteins were shown to be 
located in the nucleus and the nucleolus of COS-7 cells (figures 4.16 and 4.18). These results 
are likely to show the in vivo location of Tat, seeing how the COS-7 cells used are primate 
cells, and should contain a minimum of cellular factors not found in humans that would 
interfere with the intracellular localization. The results are also in accordance with what has 
previously been reported for the intracellular localization of the Tat86 protein (Stauber and 
Pavlakis, 1998). The Tat101 and Tat115 proteins were not shown to have differences in the 
cellular localization compared to the 72 and 86 amino acid versions of the HXB3 strain.  
Stauber and Pavlakis have suggested that the nucleolar localization of Tat is due to 
overexpression of Tat in the cells (1998), and this hypothesis seems to agree with the results 
in this study. The cells that expressed Tat in moderate amounts did not have such a distinct 
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accumulation of the Tat protein in the nucleoli. When the Tat proteins were examined by 
observing the fluorescence from EGFP, they all showed mainly nuclear, and in particular 
nucleolar, localization. The images taken with the camera could not confer that a weak 
shimmer of fluorescence can be seen in the cytoplasm. The Tat115 protein could not be 
detected when the Tat proteins were inspected by immunofluorescence. This was most likely 
due to differences in the amino acid sequence of the epitope the monoclonal antibody that was 
used, 1D9D5, binds to. This epitope has been mapped to amino acids 2-21 of Tat (Valvatne et 
al., 1996). And there are some differences in the sequence of this region between Tat101, 
which has a sequence similar to the protein that was used when the antibody was made; and 
Tat115 (figure 4.1).  
When the intracellular distribution of the Tat proteins was examined by immunofluorescence, 
there were some discrepancies. In some cells the protein was detected only in the cytoplasm 
by immunofluorescence, while the fluorescence of the EGFP moiety indicated nuclear and 
nucleolar localization. There presence of EGFP in the nucleus should exclude the possibility 
of Tat not being there. This indicates that possibly something hinders the antibodies, one or 
both, from reaching the nucleus. This could be caused by the paraformaldehyde fixation 
causing chemical crosslinking within the cells (Anne Marie Szilvay, personal 
communication). 
Methanol fixation have been reported to cause an artificial nuclear localization of some 
proteins, and one should possibly have studied the localization of Tat in live cells, as 
suggested by Richard et al. (2002). However, Stauber and Pavlakis do show that Tat-86-
EGFP does localize in the nucleus and the nucleolus both in living and in fixed cells (1998). 
This indicates that the localization of the Tat protein is undisturbed by the fixation process. 
However, any final conclusion regarding the intracellular distribution of the Tat101 and 
Tat115 proteins based on this should not be drawn. 
5.7 Future perspectives 
Several experiments could be conducted to see whether the results of the bioinformatical 
analyses accurately have predicted the properties of the Tat101 and Tat115 proteins. The 
constructed genes allow further studies of these proteins. With a Tat protein with a complete 
exon 2 available, it is be possible to conduct co-localization studies of the Tat72 and Tat101 
proteins, in order to get a final clarification on the role of the second exon-encoded parts of 
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the protein on its intracellular distribution. The tat genes could also be used in the yeast two 
hybrid system to investigate which proteins in a library the Tat proteins interact with.  
There should be further analyses of what happens during expression of the 6Xhis-Tat101 
protein that lead to several subspecies of the protein. Further attempts to purify the Tat115 
protein in order to determine whether it has trans-cellular activity should also be performed. 
The expression of this protein could be done in a different system. 
The constructed EGFP-Tat vectors can be further used in co-localization studies with other 
proteins. Or they could be used in assays determining their shuttling capabilities, like the 
heterokaryon assay used by Stauber and Pavlakis (1998), or the microinjection assay used by 
Kalland et al. (1994). 
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A Appendix 
A.1 Sequence data 
A.1.1 Tat115 sequence data 
The gene referred to as tat115 was based on the tat gene from the HIV-1 subtype O strain 
MVP5180 and has the following DNA sequence: 
 
ATG GAT CCA GTA GAT CCT GAG ATG CCC CCT TGG CAT CAC CCT GGG AGC 
AAG CCC CAA ACC CCT TGT AAT AAT TGC TAT TGC AAA AGA TGC TGC TAT 
CAT TGC TAT GTT TGT TTC ACA AAG AAG GGT TTG GGA ATC TCC CAT GGC 
AGG AAG AAG CGA AGA AGA CCA GCA GCT GCT GCA AGC TAT CCA GAT AAT 
AAA GAT CCT GTA CCA GAG CAA TCC CTG TCC CAC ACC GGC AGG AAG CAG 
AAA CGC CAG GAA GAA CAG GAG AAG AAG GTG GAG AAG GAG ACA GGC 
CCA ACT GGA CAG CCT TGC CAC CAG GAT TCT TGC AAC AGT TGT ACA CGG 
ATC TCA GGA CAA TAA 
 
The nucleotide shown in bold represents a deviation from the sequence of the gene as it is 
found in the MVP5180 strain (a guanine has been replaced by a cytosine). Marked in italics 
are the start and stop codons. 
This renders the following amino acid sequence for the Tat115 protein (one letter amino acid 
code): 
 
M D P V D P E M P P W H H P G S K P Q T P C N N C Y C K R C C Y H C Y V C F T K 
K G L G I S H G R K K R R R P A A A A S Y P D N K D P V P E Q S L S H T G R K Q K 
R Q E E Q E K K V E K E T G P T G Q P C H Q D S C N S C T R I S G Q 
 
The amino acid shown in bold marks the mutation that arose due to the nucleotide change 
mentioned above (serine97 has been replaced by a threonine). 
A.1.2 Tat101 sequence data 
The DNA sequence of the tat101 gene was based on the sequence of the tat gene from the 
HXB3 strain: 
ATG GAG CCA GTA GAT CCT AGA CTA GAG CCC TGG AAG CAT CCA GGA AGT 
CAG CCT AAA ACT GCT TGT ACC AAT TGC TAT TGT AAA AAG TGT TGC TTT 
CAT TGC CAA GTT TGT TTC ATA ACA AAA GCC TTA GGC ATC TCC TAT GGC 
AGG AAG AAG CGG AGA CAG CGA CGA AGA CCT CCT CAA GGC AGT CAG ACT 
CAT CAA GTT TCT CTA TCA AAG CAA CCC ACC TCC CAA TCC CGA GGG GAC 
CCG ACA GGC CCG AAG GAA TCG AAG AAG AAG GTG GAG AGA GAG ACA 
GAG ACA GAT CCA TTC GAT TAG 
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The nucleotide shown in bold represents a deviation from the sequence of the gene as it is 
found in the HXB3 strain (an adenine has been replaced by a cytosine). Marked in italics are 
the start and stop codons. 
This renders the following amino acid sequence for the Tat101 protein (one letter amino acid 
code): 
M E P V D P R L E P W K H P G S Q P K T A C T N C Y C K K C C F H C Q V C F I T K 
A L G I S Y G R K K R R Q R R R P P Q G S Q T H Q V S L S K Q P T S Q S R G D P T G 
P K E S K K K V E R E T E T D P F D G S T G S R  
 
HXB3 has a stop codon at position 87. In tat101 one nucleotide is changed from A to C. This 
means that the stop codon is replaced by a serine, and 14 additional amino acids are encoded 
by the gene, which is common among other strains from HIV-1 group M. 
A.1.3 Amino acid sequences of several types of Tat (from the Los 
Alamos database) 
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A.2 Computer results  
A.2.1 Protparam results for Tat101 
Number of amino acids: 101 
 
Molecular weight: 11575.2 
 
Theoretical pI: 9.64 
 
Amino acid composition: 
 
Ala (A)   2   2.0% 
Arg (R)   9   8.9% 
Asn (N)   1   1.0% 
Asp (D)   4   4.0% 
Cys (C)   7   6.9% 
Gln (Q)   8   7.9% 
Glu (E)   6   5.9% 
Gly (G)   6   5.9% 
His (H)   3   3.0% 
Ile (I)   2   2.0% 
Leu (L)   3   3.0% 
Lys (K)  12  11.9% 
Met (M)   1   1.0% 
Phe (F)   3   3.0% 
Pro (P)  11  10.9% 
Ser (S)   8   7.9% 
Thr (T)   8   7.9% 
Trp (W)   1   1.0% 
Tyr (Y)   2   2.0% 
Val (V)   4   4.0% 
 
Asx (B)   0   0.0% 
Glx (Z)   0   0.0% 
Xaa (X)   0   0.0% 
 
Total number of negatively charged residues (Asp + Glu): 10 
Total number of positively charged residues (Arg + Lys): 21 
 
 
Extinction coefficients: 
 
Conditions: 6.0 M guanidium hydrochloride 
            0.02 M phosphate buffer 
            pH 6.5 
 
Extinction coefficients are in units of  M-1 cm-1 . 
 
The first table lists values computed assuming ALL Cys  
residues appear as half cystines, whereas the second table  
assumes that NONE do.  
 
                      276     278     279     280     282 
                       nm      nm      nm      nm      nm 
Ext. coefficient     8735    8781    8710    8610    8360 
Abs 0.1% (=1 g/l)   0.755   0.759   0.752   0.744   0.722 
 
 
 
                      276     278     279     280     282 
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                       nm      nm      nm      nm      nm 
Ext. coefficient     8300    8400    8350    8250    8000 
Abs 0.1% (=1 g/l)   0.717   0.726   0.721   0.713   0.691 
 
 
Estimated half-life: 
 
The N-terminal of the sequence considered is M (Met). 
 
The estimated half-life is: 30 hours (mammalian reticulocytes, in vitro). 
                            >20 hours (yeast, in vivo). 
                            >10 hours (Escherichia coli, in vivo). 
 
 
Instability index: 
 
The instability index (II) is computed to be 65.13 
This classifies the protein as unstable. 
 
 
 
Aliphatic index: 32.77 
 
Grand average of hydropathicity (GRAVY): -1.290 
With his-tag: 
Number of amino acids: 140 
 
Molecular weight: 15890.1 
 
Theoretical pI: 10.14 
 
Amino acid composition: 
 
Ala (A)  10   7.1% 
Arg (R)  14  10.0% 
Asn (N)   1   0.7% 
Asp (D)   4   2.9% 
Cys (C)   7   5.0% 
Gln (Q)  10   7.1% 
Glu (E)   6   4.3% 
Gly (G)  11   7.9% 
His (H)   9   6.4% 
Ile (I)   3   2.1% 
Leu (L)   4   2.9% 
Lys (K)  13   9.3% 
Met (M)   5   3.6% 
Phe (F)   3   2.1% 
Pro (P)  12   8.6% 
Ser (S)  10   7.1% 
Thr (T)   9   6.4% 
Trp (W)   2   1.4% 
Tyr (Y)   3   2.1% 
Val (V)   4   2.9% 
 
Asx (B)   0   0.0% 
Glx (Z)   0   0.0% 
Xaa (X)   0   0.0% 
 
Total number of negatively charged residues (Asp + Glu): 10 
Total number of positively charged residues (Arg + Lys): 27 
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Atomic composition: 
 
Carbon      C        678 
Hydrogen    H       1084 
Nitrogen    N        226 
Oxygen      O        194 
Sulfur      S         12 
 
Formula: C H N O S12 678 1084 226 194
Total number of atoms: 2194 
 
Extinction coefficients: 
 
Conditions: 6.0 M guanidium hydrochloride 
            0.02 M phosphate buffer 
            pH 6.5 
 
Extinction coefficients are in units of  M-1 cm-1 . 
 
The first table lists values computed assuming ALL Cys  
residues appear as half cystines, whereas the second table  
assumes that NONE do.  
 
                      276     278     279     280     282 
                       nm      nm      nm      nm      nm 
Ext. coefficient    15585   15781   15715   15580   15160 
Abs 0.1% (=1 g/l)   0.981   0.993   0.989   0.980   0.954 
 
User-provided sequence: 
 
      1          11         21         31         41         51          
      |          |          |          |          |          |           
    1 MEPVDPRLEP WKHPGSQPKT ACTNCYCKKC CFHCQVCFIT KALGISYGRK KRRQRRRPPQ    
60 
   61 GSQTHQVSLS KQPTSQSRGD PTGPKESKKK VERETETDPF D 
 
A.2.2 Protparam results for Tat115 
Number of amino acids: 115 
 
Molecular weight: 13024.7 
 
Theoretical pI: 9.06 
 
Amino acid composition: 
 
Ala (A)   4   3.5% 
Arg (R)   8   7.0% 
Asn (N)   4   3.5% 
Asp (D)   5   4.3% 
Cys (C)  10   8.7% 
Gln (Q)   8   7.0% 
Glu (E)   7   6.1% 
Gly (G)   8   7.0% 
His (H)   6   5.2% 
Ile (I)   2   1.7% 
Leu (L)   2   1.7% 
Lys (K)  12  10.4% 
Met (M)   2   1.7% 
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Phe (F)   1   0.9% 
Pro (P)  13  11.3% 
Ser (S)   8   7.0% 
Thr (T)   6   5.2% 
Trp (W)   1   0.9% 
Tyr (Y)   4   3.5% 
Val (V)   4   3.5% 
 
Asx (B)   0   0.0% 
Glx (Z)   0   0.0% 
Xaa (X)   0   0.0% 
 
Total number of negatively charged residues (Asp + Glu): 12 
Total number of positively charged residues (Arg + Lys): 20 
 
 
Extinction coefficients: 
 
Conditions: 6.0 M guanidium hydrochloride 
            0.02 M phosphate buffer 
            pH 6.5 
 
Extinction coefficients are in units of  M-1 cm-1 . 
 
The first table lists values computed assuming ALL Cys  
residues appear as half cystines, whereas the second table  
assumes that NONE do.  
 
                      276     278     279     280     282 
                       nm      nm      nm      nm      nm 
Ext. coefficient    11925   11835   11640   11410   11000 
Abs 0.1% (=1 g/l)   0.916   0.909   0.894   0.876   0.845 
 
 
 
                      276     278     279     280     282 
                       nm      nm      nm      nm      nm 
Ext. coefficient    11200   11200   11040   10810   10400 
Abs 0.1% (=1 g/l)   0.860   0.860   0.848   0.830   0.798 
 
 
Estimated half-life: 
 
The N-terminal of the sequence considered is M (Met). 
 
The estimated half-life is: 30 hours (mammalian reticulocytes, in vitro). 
                            >20 hours (yeast, in vivo). 
                            >10 hours (Escherichia coli, in vivo). 
 
 
Instability index: 
 
The instability index (II) is computed to be 75.99 
This classifies the protein as unstable. 
 
 
 
Aliphatic index: 27.13 
 
Grand average of hydropathicity (GRAVY): -1.343 
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A.2.3 Psipred results  
Key 
 
Conf: Confidence (0=low, 9=high) 
Pred: Predicted secondary structure (H=helix, E=strand, C=coil) 
AA: Target sequence 
 
Tat101 
Conf: 988888877543578887788875200123466467774235233147787666687888 
Pred: CCCCCCCCCCCCCCCCCCCCCCCCCCCHHHHHHHHHHHHHCCCEECCCCCCCCCCCCCCC 
  AA: MEPVDPRLEPWKHPGSQPKTACTNCYCKKCCFHCQVCFITKALGISYGRKKRRQRRRPPQ 
              10        20        30        40        50        60 
 
Conf: 78888887778888888777667501233333331267889 
Pred: CCCCCCCCCCCCCCCCCCCCCCCCCHHHHHHHHHHCCCCCC 
  AA: GSQTHQVSLSKQPTSQSRGDPTGPKESKKKVERETETDPFD 
              70        80        90       100 
Tat115 
Conf: 988888877421468887788875300011245256664225234036787678878877 
Pred: CCCCCCCCCCCCCCCCCCCCCCCCCCCHHHHHHHHHHHHHCCCEEECCCCCCCCCCCCCC 
  AA: MDPVDPEMPPWHHPGSKPQTPCNNCYCKRCCYHCYVCFTKKGLGISHGRKKRRRPAAAAS 
              10        20        30        40        50        60 
 
Conf: 8877665545688788777768521013421110468888646544322345689 
Pred: CCCCCCCCCCCCCCCCCCCCCCCCCCEEEEEEECCCCCCCCCCCCCCCCCCCCCC 
  AA: YPDNKDPVPEQSLSHTGRKQKRQEEQEKKVEKETGPTGQPCHQDSCNSCTRISGQ 
              70        80        90       100       110   
A.2.4 PSORT II results for Tat101 
Results of Subprograms 
PSG:  a new signal peptide prediction method 
      N-region:  length 9;  pos.chg 1;  neg.chg 3 
      H-region:  length 2;  peak value   0.00 
      PSG score:  -4.40 
 
GvH:  von Heijne's method for signal seq. recognition 
      GvH score (threshold: -2.1):  -4.52 
      possible cleavage site: between 44 and 45 
 
>>> Seems to have no N-terminal signal peptide 
 
ALOM: Klein et al's method for TM region allocation 
      Init position for calculation: 1 
      Tentative number of TMS(s) for the threshold  0.5:   0 
      number of TMS(s) .. fixed 
      PERIPHERAL  Likelihood =  2.65 (at 30) 
      ALOM score:   2.65  (number of TMSs: 0) 
 
MITDISC: discrimination of mitochondrial targeting seq 
      R content:       0       Hyd Moment(75):  2.80 
      Hyd Moment(95):  7.47    G content:       0 
      D/E content:     2       S/T content:     0 
      Score: -7.35 
 
Gavel: prediction of cleavage sites for mitochondrial preseq 
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      cleavage site motif not found 
 
NUCDISC: discrimination of nuclear localization signals 
      pat4: RKKR (5) at   49 
      pat4: KKRR (5) at   50 
      pat4: RRRP (4) at   55 
      pat7: PKESKKK (3) at   84 
      bipartite: none 
      content of basic residues:  20.8% 
      NLS Score:  1.61 
 
KDEL: ER retention motif in the C-terminus: none 
 
ER Membrane Retention Signals: none 
 
SKL: peroxisomal targeting signal in the C-terminus: none 
 
SKL2: 2nd peroxisomal targeting signal:  none 
 
VAC: possible vacuolar targeting motif: none 
 
RNA-binding motif: none 
 
Actinin-type actin-binding motif: 
      type 1: none 
      type 2: none 
 
NMYR: N-myristoylation pattern : none 
 
Prenylation motif: none 
 
memYQRL: transport motif from cell surface to Golgi: none 
 
Tyrosines in the tail: none 
 
Dileucine motif in the tail: none 
 
checking 63 PROSITE DNA binding motifs:  none 
 
checking 71 PROSITE ribosomal protein motifs:  none 
 
checking 33 PROSITE prokaryotic DNA binding motifs:  none 
 
NNCN: Reinhardt's method for Cytplasmic/Nuclear discrimination 
      Prediction: nuclear 
      Reliability: 94.1 
 
COIL: Lupas's algorithm to detect coiled-coil regions 
      total: 0 residues  
Results of the k-NN Prediction 
k = 9/23  
  78.3 %: nuclear 
  13.0 %: cytoskeletal 
   4.3 %: cytoplasmic 
   4.3 %: vesicles of secretory system 
 
>> prediction for QUERY is nuc (k=23) 
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A.2.5 PSORT II results for Tat115 
Results of Subprograms 
PSG:  a new signal peptide prediction method 
      N-region:  length 7;  pos.chg 0;  neg.chg 3 
      H-region:  length 9;  peak value   0.00 
      PSG score:  -4.40 
 
GvH:  von Heijne's method for signal seq. recognition 
      GvH score (threshold: -2.1): -10.54 
      possible cleavage site: between 48 and 49 
 
>>> Seems to have no N-terminal signal peptide 
 
ALOM: Klein et al's method for TM region allocation 
      Init position for calculation: 1 
      Tentative number of TMS(s) for the threshold  0.5:   0 
      number of TMS(s) .. fixed 
      PERIPHERAL  Likelihood =  9.28 (at 30) 
      ALOM score:   9.28  (number of TMSs: 0) 
 
MITDISC: discrimination of mitochondrial targeting seq 
      R content:       0       Hyd Moment(75):  3.13 
      Hyd Moment(95):  7.96    G content:       0 
      D/E content:     2       S/T content:     0 
      Score: -7.24 
 
Gavel: prediction of cleavage sites for mitochondrial preseq 
      cleavage site motif not found 
 
NUCDISC: discrimination of nuclear localization signals 
      pat4: RKKR (5) at   49 
      pat4: KKRR (5) at   50 
      pat4: KRRR (5) at   51 
      pat4: RRRP (4) at   52 
      pat7: none 
      bipartite: KKGLGISHGRKKRRRPA at   40 
      content of basic residues:  17.4% 
      NLS Score:  1.21 
 
KDEL: ER retention motif in the C-terminus: none 
 
ER Membrane Retention Signals: none 
 
SKL: peroxisomal targeting signal in the C-terminus: none 
 
SKL2: 2nd peroxisomal targeting signal:  none 
 
VAC: possible vacuolar targeting motif: none 
 
RNA-binding motif: none 
 
Actinin-type actin-binding motif: 
      type 1: none 
      type 2: none 
 
NMYR: N-myristoylation pattern : none 
 
Prenylation motif: none 
 
memYQRL: transport motif from cell surface to Golgi: none 
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Tyrosines in the tail: none 
 
Dileucine motif in the tail: none 
 
checking 63 PROSITE DNA binding motifs:  none 
 
checking 71 PROSITE ribosomal protein motifs:  none 
 
checking 33 PROSITE prokaryotic DNA binding motifs:  none 
 
NNCN: Reinhardt's method for Cytplasmic/Nuclear discrimination 
      Prediction: nuclear 
      Reliability: 94.1 
 
COIL: Lupas's algorithm to detect coiled-coil regions 
      total: 0 residues  
 
 
 
Results of the k-NN Prediction 
k = 9/23  
  69.6 %: nuclear 
  13.0 %: cytoskeletal 
   4.3 %: Golgi 
   4.3 %: plasma membrane 
   4.3 %: vesicles of secretory system 
   4.3 %: cytoplasmic 
 
>> prediction for QUERY is nuc (k=23) 
A.2.6 ScanProsite results for Tat101 
PROSITE Release 17.22, of 11-Oct-2002  
 
>PDOC00005 PS00005 PKC_PHOSPHO_SITE Protein kinase C phosphorylation site 
[pattern] [Warning: pattern with a high probability of occurrence].  
       87 - 89  SkK 
>PDOC00006 PS00006 CK2_PHOSPHO_SITE Casein kinase II phosphorylation site 
[pattern] [Warning: pattern with a high probability of occurrence].  
       77 - 80  SrgD 
       95 - 98  TetD 
>PDOC00008 PS00008 MYRISTYL N-myristoylation site [pattern] [Warning: pattern with 
a high probability of occurrence].  
       44 - 49  GIsyGR 
>PDOC00009 PS00009 AMIDATION Amidation site [pattern] [Warning: pattern with a 
high probability of occurrence].  
       47 - 50  yGRK 
>PDOC00016 PS00016 RGD Cell attachment sequence [pattern] [Warning: pattern with a 
high probability of occurrence].  
       78 - 80  RGD 
>PDOC50099 PS50311 CYS_RICH Cysteine-rich region [profile].  
       22 - 37  CtncyckkccfhcqvC                 
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A.2.7 ScanProsite results for Tat115  
PROSITE Release 17.22, of 11-Oct-2002  
 
>PDOC00005 PS00005 PKC_PHOSPHO_SITE Protein kinase C phosphorylation site 
[pattern] [Warning: pattern with a high probability of occurrence].  
       39 - 41  TkK 
       76 - 78  TgR 
>PDOC00006 PS00006 CK2_PHOSPHO_SITE Casein kinase II phosphorylation site 
[pattern] [Warning: pattern with a high probability of occurrence].  
       60 - 63  SypD 
>PDOC00008 PS00008 MYRISTYL N-myristoylation site [pattern] [Warning: pattern with 
a high probability of occurrence].  
       42 - 47  GLgiSH 
       44 - 49  GIshGR 
>PDOC00009 PS00009 AMIDATION Amidation site [pattern] [Warning: pattern with a 
high probability of occurrence].  
       47 - 50  hGRK 
       76 - 79  tGRK 
>PDOC00015 PS00015 NUCLEAR Bipartite nuclear targeting sequence [rule] [Warning: 
rule with a high probability of occurrence].  
       40 - 56  KKglgishgrkkrrrpa 
>PDOC50099 PS50311 CYS_RICH Cysteine-rich region [profile].  
       22 - 37  CnncyckrccyhcyvC                 
A.2.8 Blast 2 Sequences (Tat101 and Tat115) 
Sequence 1 lcl|seq_1  Length 101 (1 .. 101) 
      
Sequence 2 lcl|seq_2  Length 115 (1 .. 115) 
  
2 
 1 
 
NOTE:The statistics (bitscore and expect value) is calculated based on the size of nr database 
Score = 92.8 bits (227), Expect = 6e-19 
Identities = 49/100 (49%), Positives = 61/100 (61%), Gaps = 11/100 (11%) 
 
 
 
Query: 1  MEPVDPRLEPWKHPGSQPKTACTNCYCKKCCFHCQVCFITKALGISYXXXXXXXXXXXXX 60 
          M+PVDP + PW HPGS+P+T C NCYCK+CC+HC VCF  K LGIS+              
Sbjct: 1  MDPVDPEMPPWHHPGSKPQTPCNNCYCKRCCYHCYVCFTKKGLGISHGRKKRRRPAAAAS 60 
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Query: 61 XSQTHQVSLSKQPTSQSRGDPTGPK-----ESKKKVERET 95 
                   +K P  +     TG K     E +KKVE+ET 
Sbjct: 61 YPD------NKDPVPEQSLSHTGRKQKRQEEQEKKVEKET 94 
CPU time:     0.08 user secs.     0.01 sys. secs     0.09 total secs. 
 
Gapped 
Lambda     K      H 
   0.315    0.131    0.429  
 
Gapped 
Lambda     K      H 
   0.270   0.0470    0.230  
 
 
Matrix: BLOSUM62 
Gap Penalties: Existence: 11, Extension: 1 
Number of Hits to DB: 184 
Number of Sequences: 0 
Number of extensions: 19 
Number of successful extensions: 1 
Number of sequences better than 10.0: 1 
Number of HSP's better than 10.0 without gapping: 1 
Number of HSP's successfully gapped in prelim test: 0 
Number of HSP's that attempted gapping in prelim test: 0 
Number of HSP's gapped (non-prelim): 1 
length of query: 101 
length of database: 181,542,687 
effective HSP length: 46 
effective length of query: 55 
effective length of database: 98,859,895 
effective search space: 5437294225 
effective search space used: 5437294225 
T: 9 
A: 40 
X1: 16 ( 7.3 bits) 
X2: 128 (49.9 bits) 
X3: 128 (49.9 bits) 
S1: 41 (21.6 bits) 
S2: 64 (29.3 bits) 
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A.2.9 Blast results for the EK domain of Tat115 
 
 
 
 
                                                                 Score    E 
Sequences producing significant alignments:                      (bits) 
Value 
 
gi|14041640|emb|CAC38424.1|  (AJ302647) tat protein [Human i...    30   2.6    
gi|20853427|ref|XP_136788.1|  (XM_136788) similar to gag pro...    29   8.3    
gi|21402726|ref|NP_658711.1|  (NC_003995) hypothetical prote...    29   8.3    
gi|23510183|ref|NP_702849.1|  (NC_004318) hypothetical prote...    27   20     
gi|7243125|dbj|BAA92610.1|  (AB037793) KIAA1372 protein [Hom...    27   20    
 gi|20483065|ref|XP_166244.1|  (XM_166244) similar to KIAA137...    27   20    
 gi|2108169|gb|AAC57424.1|  (U89134) tat protein [Simian-Huma...    27   27     
gi|9629920|ref|NP_046127.1|  (NC_001870) tat [Simian-Human i...    27   27     
gi|1055034|gb|AAA81040.1|  (U39362) TAT protein [Human immun...    27   27     
gi|1469311|gb|AAB05047.1|  (U04908) tat protein [Human immun...    27   27     
gi|23508435|ref|NP_701104.1|  (NC_004315) hypothetical prote...    27   36     
gi|16272277|ref|NP_438489.1|  (NC_000907) ribonuclease T (rn...    27   36     
gi|11497667|ref|NP_068888.1|  (NC_000917) hypothetical prote...    27   36     
gi|6321540|ref|NP_011617.1|  (NC_001139) Nucleolar protein p...    26   49     
gi|2497693|sp|Q63805|A1AI_MOUSE  Alpha-1-acid glycoprotein 3...    26   49     
gi|7490230|pir||T41163  cholinephosphate cytidylyltransferas...    26   65     
gi|18376116|emb|CAD21182.1|  (AL669998) conserved hypothetic...    26   65     
gi|19076048|ref|NP_588548.1|  (NC_003421) putative cholineph...    26   65     
gi|6503222|gb|AAF14644.1|AF163772_4  (AF163772) 7138.4 [Leis...    26   65     
gi|15227342|ref|NP_179292.1|  (NM_127253) hypothetical prote...    26   65     
gi|17558460|ref|NP_503869.1|  (NM_071468) C36C5.12.p [Caenor...    26   65    
 gi|19386842|dbj|BAB86220.1|  (AP003922) contains ESTs AU0939...    26   65     
gi|10383785|ref|NP_009943.2|  (NC_001135) Cwh43p [Saccharomy...    25   87     
gi|23482863|gb|EAA18721.1|  (AABL01002201) glutamine-asparag...    25   87     
gi|10733345|gb|AAG21972.2|AF257652_1  (AF257652) hexokinase-...    25   87     
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gi|140464|sp|P25618|YCQ7_YEAST  HYPOTHETICAL 107.9 KD PROTEI...    25   87     
gi|21593329|gb|AAM65278.1|  (AY087741) unknown [Arabidopsis ...    25   87     
gi|15238732|ref|NP_200152.1|  (NM_124719) putative protein; ...    25   87     
gi|20808632|ref|NP_623803.1|  (NC_003869) DNA-directed RNA p...    25   87     
gi|15241804|ref|NP_198192.1|  (NM_122723) putative protein; ...    25   87     
gi|23484411|gb|EAA19749.1|  (AABL01002670) hypothetical prot...    25   87     
gi|23488770|gb|EAA21392.1|  (AABL01000545) hypothetical prot...    25   87     
gi|23480318|gb|EAA16908.1|  (AABL01001547) Drosophila melano...    25   87     
gi|15233209|ref|NP_191737.1|  (NM_116043) putative protein; ...    25   87     
gi|17233362|ref|NP_490452.1|  (NC_003276) unknown protein [N...    25   117    
gi|21298777|gb|EAA10922.1|  (AAAB01008960) agCP6519 [Anophel...    25   117    
gi|19114260|ref|NP_593348.1|  (NC_003424) putative ATP-depen...    25   117    
gi|21038850|emb|CAD31825.1|  (AL132948) Y39B6A.30 [Caenorhab...    25   117    
gi|7513208|pir||T08880  NMDA receptor-binding protein yotiao...    25   117    
gi|17565568|ref|NP_507714.1|  (NM_075313) Y39B6A.v.p [Caenor...    25   117   
 gi|22538389|ref|NP_671695.1|  (NM_147166) A kinase anchor pr...    25   117   
 gi|4584423|emb|CAB40713.1|  (AJ131693) AKAP450 protein [Homo...    25   117   
 gi|20128861|ref|NP_569906.1|  (NM_130550) EG:8D8.4 gene prod...    25   117   
 gi|7416518|dbj|BAA93904.1|  (AB034447) Tat protein [Human im...    25   117    
gi|22538391|ref|NP_671700.1|  (NM_147171) A kinase anchor pr...    25   117   
 gi|21038841|emb|CAD31816.1|  (AL132948) Y39B6A.18 [Caenorhab...    25   117    
gi|23094539|emb|CAD45758.1|  (AL766843) Unknown [Streptococc...    25   117    
gi|23026768|gb|ZP_00065241.1|  (NZ_AAAT01000002) hypothetica...    25   117    
gi|22536299|ref|NP_687150.1|  (NC_004116) ribose ABC transpo...    25   117    
gi|22538393|ref|NP_671714.1|  (NM_147185) A kinase anchor pr...    25   117   
 gi|4558862|gb|AAD22767.1|AF083037_1  (AF083037) A-kinase anc...    25   117   
 gi|15792868|ref|NP_282691.1|  (NC_002163) putative transcrip...    25   117    
gi|3645944|gb|AAC60380.1|  (AC000066) yotiao [Homo sapiens]        25   117   
 gi|17539938|ref|NP_501328.1|  (NM_068927) F20D12.2.p [Caenor...    25   117   
 gi|5051743|dbj|BAA78718.1|  (AB019691) Centrosome- and Golgi...    25   117   
 gi|21483398|gb|AAM52674.1|  (AY122162) LD23562p [Drosophila ...    25   117   
 gi|17565546|ref|NP_507706.1|  (NM_075305) Y39B6A.n.p [Caenor...    25   117   
 gi|135171|sp|P27058|SYST_LYCES  Systemin precursor >gi|74890...    25   117    
gi|10834807|gb|AAG23833.1|AF290425_1  (AF290425) NADPH cytoc...    25   117    
gi|7489266|pir||T06993  prosystemin PRO1 - potato >gi|291128...    25   117    
gi|22538387|ref|NP_005742.4|  (NM_005751) A kinase anchor pr...    25   117   
 gi|23490500|gb|EAA22262.1|  (AABL01000770) hypothetical prot...    24   157    
gi|21281669|ref|NP_060899.1|  (NM_018429) transcription fact...    24   157   
 gi|18583964|ref|XP_101952.1|  (XM_101952) hypothetical prote...    24   157   
 gi|19113217|ref|NP_596425.1|  (NC_003423) hexose transporter...    24   157    
gi|18405336|ref|NP_566816.1|  (NM_113650) expressed protein;...    24   157    
gi|15792002|ref|NP_281825.1|  (NC_002163) putative DNA repai...    24   157    
gi|11277423|pir||T43533  hexose transport protein Ght2 - fis...    24   157    
gi|11096171|gb|AAG30220.1|AF298151_1  (AF298151) RNA polymer...    24   157   
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gi|17564292|ref|NP_507103.1|  (NM_074702) Zinc finger, C4 ty...    24   157   
 gi|1352419|sp|P20810|ICAL_HUMAN  Calpain inhibitor (Calpasta...    24   157    
gi|480379|pir||S36779  ribosome-binding protein p34 - rat >g...    24   157    
gi|12056962|gb|AAG48151.1|AF327443_1  (AF327443) calpastatin...    24   157   
 gi|17559086|ref|NP_505097.1|  (NM_072696) D1014.5.p [Caenorh...    24   157   
 gi|16553841|dbj|BAB71602.1|  (AK057871) unnamed protein prod...    24   157    
gi|12545390|gb|AAA52759.2|  (M86257) calpastatin [Homo sapiens]    24   157    
gi|17530149|gb|AAL40720.1|AF402771_1  (AF402771) calreticuli...    24   157    
gi|23478719|gb|EAA15730.1|  (AABL01001174) hypothetical prot...    24   157    
gi|5053101|gb|AAD38850.1|AF156027_1  (AF156027) calcium/calm...    24   157    
gi|21361567|ref|NP_001741.2|  (NM_001750) calpastatin [Homo ...    24   157   
 gi|21554138|gb|AAM63218.1|  (AY086009) unknown [Arabidopsis ...    24   157    
gi|951315|gb|AAB60371.1|  (U31345) calpastatin [Homo sapiens]      24   157    
gi|5819094|gb|AAC50136.2|  (U26724) calpastatin [Homo sapiens]     24   157    
gi|23480647|gb|EAA17150.1|  (AABL01000162) hypothetical prot...    24   157    
gi|180975|gb|AAA52066.1|  (M28230) calpastatin [Homo sapiens]      24   157    
gi|7305547|ref|NP_038950.1|  (NM_013922) zinc finger protein...    24   157   
 gi|226919|prf||1611327A  calpastatin [Homo sapiens]                24   157    
gi|2754612|dbj|BAA24152.1|  (AB010030) outer arm dynein ligh...    24   157    
gi|12232589|emb|CAC21448.1|  (AJ279120) TFNR [Homo sapiens]        24   157    
gi|11096173|gb|AAG30221.1|AF298152_1  (AF298152) RNA polymer...    24   157   
 gi|2134859|pir||A38091  calpastatin, long form - human (frag...    24   157    
gi|20095055|ref|NP_614902.1|  (NC_003551) DNA-binding protei...    24   211    
gi|23594238|ref|XP_177346.1|  (XM_177346) similar to Fragile...    24   211   
 gi|23501918|ref|NP_698045.1|  (NC_004310) sensory box histid...    24   211    
gi|17987230|ref|NP_539864.1|  (NC_003317) Sensory Transducti...    24   211    
gi|541239|pir||S42875  dihydrolipoamide S-succinyltransferas...    24   211    
gi|727184|gb|AAA64261.1|  (L40990) tat [Simian immunodeficie...    24   211    
gi|23509084|ref|NP_701752.1|  (NC_004316) erythrocyte membra...    24   211    
gi|23041665|gb|ZP_00073108.1|  (NZ_AAAU01000025) hypothetica...    24   211    
gi|14041630|emb|CAC38433.1|  (AJ302646) tat protein [Human i...    24   211    
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A.3 Plasmid maps 
pEGFP-C1, provided by Clontech (GenBank Accession #: U55763) 
 
Figure 2.1: An overview of the most important features of the pEGFP-C1 plasmid. 
This vector encodes the enhanced green fluorescent protein, EGFP, and neomycin/kanamycin 
resistance for selection in eukaryote cells and bacteria. The vector also contains SV40 and 
pUC origins of replication, as well as a multiple cloning site, MCS, after the EGFP coding 
region. When a gene is cloned into the MCS and it is in frame with the EGFP gene then the 
vector will express a fusion protein when in eukaryote cells (figure 2.1). 
pEGFP-Tat72, kindly provided by Vibeke Andresen, UiB, Norway. 
The pEGFP-C1 vector with the first exon of tat from the HXB3 clone cloned in frame with 
EGFP. Expresses a fusion protein, EGFP-Tat72, when in eukaryote cell lines. (An overview 
of the most important features of this plasmid can be seen in figure 4.11) 
pEGFP-Tat86, kindly provided by Vibeke Andresen, UiB, Norway. 
The pEGFP-C1 vector with the first 86 codons of tat from the HXB3 clone cloned in frame 
with EGFP. The 87th codon of tat from this clone is a stop codon. Expresses a fusion protein, 
EGFP-Tat86, when in eukaryote cell lines. (An overview of the most important features of 
this plasmid can be seen in figure 4.11) 
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pCR-Blunt II-TOPO, provided by Invitrogen. 
 
Figure 2.2: An overview of the most important features of the pCR-Blunt II-TOPO plasmid, as well as an overview of the 
cloning site. 
This vector is part of the Zero BluntTM TOPOTM PCR Cloning kit from Invitrogen. It is used 
to clone blunt-end PCR products. The vector is supplied linearized with vaccinia virus 
topoisomerase I covalently bound to the 3’ end, which means that ligation with a blunt-end 
PCR product will occur spontaneously (figure 2.2). 
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pRSET-C, provided by Invitrogen. 
 
 
Figure 2.3: A map of the pRSET expression vector and of its multiple cloning site. There are three versions of this 
expression vector; the difference between them consists of a variable sequence-segment. In the different vectors the 
restriction sites are found in different reading frames due to this. 
pRSET C is a bacterial expression vector (figure 2.3). A protein expressed from a gene 
inserted into the MCS will have an additional 30 something residues in the N-terminus. The 
exact number of additional amino acids depends on which restriction sites have been used 
when inserting the gene. A 6xhis-tag and an Enterokinase cleavage site is added to the N-
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terminus of proteins expressed from this vector. The his-tag makes purification of the 
expressed protein possible by affinity chromatography, and the Enterokinase cleavage site 
makes it possible to remove most of the residues that have been added to the N-terminus of 
the protein.  This can be useful seeing how extra residues may impair the function of 
expressed proteins. However these additional residues have previously been shown not to 
abolish transcriptional activity of either the Tat86 protein (Erik Stensrud, unpublished results) 
or the Tat72 protein (Staalesen, 2000). 
LTR-CAT, kindly provided by Vibeke Andresen, UiB, Norway. 
LTR-CAT is a reporter plasmid. It has been made using the psDred-N1 vector (Clontech). 
The CMV promoter has been replaced by the HIV-1 LTR. The HIV-1 LTR promoter 
(nucleotide –167 to +80) comes from the IIIextatIII plasmid (Dana-Farber). The 
chloramphenicol transferase (CAT) is not in reading frame with the gene encoding RFP. This 
results in the Tat dependent construct LTR-CAT. Since the LTR promoter is dependent on Tat 
to function properly, CAT will only be expressed when Tat protein is present. This plasmid 
can then be used to test the function of the various Tat proteins, or to examine whether 
extracellular Tat has been taken up by cells. 
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